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experienced by up to 55% of HIV+ individuals despite viral suppression by combined antiretroviral therapy.
Reasons for the persistence of this disease are unknown, but may be related to both the presence of HIV-
infected macrophages in the central nervous system as well as neurotoxicity of antiretroviral drugs. In this
thesis, we identified two independent mechanisms of HIV-associated and antiretroviral-associated toxicity
that may each contribute distinctly to HAND neuropathogenesis. First, we showed that β-site amyloid
precursor protein cleaving enzyme 1 (BACE1), which may play a role in the onset and progression of
Alzheimer’s Disease, was both increased in HIV+ patient brains and required for HIV-associated neurotoxicity
in vitro. The BACE1 cleavage target amyloid precursor protein (APP) also mediated toxicity and was required
for neuroprotective effects of BACE1 inhibition. Second, we showed that two frontline treatment
antiretroviral drugs have neurotoxic potential in vitro and that neurotoxicity of antiretrovirals is highly
variable both across and within drug classes. Neurotoxicity of one drug, lopinavir, was mediated by oxidative
stress. Taken together, these data indicate that HIV and antiretrovirals may contribute to HAND persistence
and that both BACE1 inhibitors and drugs targeting oxidative stress may be effective as adjunctive
therapeutics in HIV+ patients.
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ABSTRACT 
HIV AND ANTIRETROVIRALS IN THE CENTRAL NERVOUS SYSTEM: 
MOLECULAR MECHANISMS OF COGNITIVE IMPAIRMENT  
 
Anna L Stern 
Kelly Jordan-Sciutto 
 
HIV-associated neurocognitive disorder (HAND) describes a wide range 
of cognitive impairments experienced by up to 55% of HIV+ individuals 
despite viral suppression by combined antiretroviral therapy. Reasons 
for the persistence of this disease are unknown, but may be related to 
both the presence of HIV-infected macrophages in the central nervous 
system as well as neurotoxicity of antiretroviral drugs. In this thesis, we 
identified two independent mechanisms of HIV-associated and 
antiretroviral-associated toxicity that may each contribute distinctly to 
HAND neuropathogenesis. First, we showed that β-site amyloid 
precursor protein cleaving enzyme 1 (BACE1), which may play a role in 
the onset and progression of Alzheimer’s Disease, was both increased 
in HIV+ patient brains and required for HIV-associated neurotoxicity in 
vitro. The BACE1 cleavage target amyloid precursor protein (APP) also 
 vii
mediated toxicity and was required for neuroprotective effects of BACE1 
inhibition. Second, we showed that two frontline treatment antiretroviral 
drugs have neurotoxic potential in vitro and that neurotoxicity of 
antiretrovirals is highly variable both across and within drug classes. 
Neurotoxicity of one drug, lopinavir, was mediated by oxidative stress. 
Taken together, these data indicate that HIV and antiretrovirals may 
contribute to HAND persistence and that both BACE1 inhibitors and 
drugs targeting oxidative stress may be effective as adjunctive 
therapeutics in HIV+ patients.     
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CHAPTER 1: INTRODUCTION 
 
 Human immunodeficiency virus (HIV) affects 36.9 million people 
worldwide (UNAIDS 2015) and is currently incurable. Although the 
disease can be well managed with combined antiretroviral therapy 
(cART), cART fails to eradicate the virus from the body even after 
decades of use (Mzingwane and Tiemessen 2017), has severe side 
effects (Bhatti et al. 2016), and does not decrease the incidence of HIV-
associated cognitive symptoms (Saylor et al. 2016). Moreover, due to 
the prevalence of HIV in resource poor areas such as sub-Saharan 
Africa, 22 million HIV+ individuals do not have access to cART (UNAIDS 
2015). Hence, the quests for an HIV cure (Melkova et al. 2017) and 
vaccine (Pegu et al. 2017) remain urgent priorities across the globe.  
 Based on the insurmountable nature of these challenges thus far, 
scientists and doctors are in constant efforts to advance the landscape 
of antiretroviral drugs (ARVs). Improvements since the advent of cART 
in 1996 have been numerous, including introduction of ARVs with better 
viral suppression, more convenient dosing regimens, and lower 
incidence of side effects (Günthard et al. 2016). Somewhat bafflingly, 
however, none of these advances nor the advent of cART itself has been 
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able to reduce the incidence of neurological complications associated 
with the HIV diagnosis (Saylor et al. 2016). There are likely multiple 
modes by which these complications occur (Etherton et al. 2015; Kaul 
2008), and this multifactorial causality in addition to the unique 
challenges posed by CNS-focused HIV research (Ellis and Letendre 
2016) have hindered the ability to confidently identify therapeutic 
targets. This dissertation will encompass a detailed discussion on the 
potential factors driving cognitive symptoms in HIV as well as provide 
original data and interpretation regarding new therapeutic avenues to 
pursue.  
  
The dynamic diagnosis of HIV-associated neurocognitive 
disorder  
 Neurological complications diagnosed in HIV+ individuals are 
currently termed HIV-associated neurocognitive disorder, or HAND 
(Antinori et al. 2007). Although the prevalence of HAND did not decrease 
with the advent of cART in 1996, the nature and severity of the disease 
has dramatically shifted (Saylor et al. 2016; Gelman 2015). Moreover, 
as doctors and scientists navigate the novel landscape of a majority 
HIV+ population over 50 (Valcour 2013), combined effects of aging and 
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HAND promise to further complicate efforts toward precise diagnosis 
and treatment (Hellmuth et al. 2014).    
 The first published description of HAND, which was then called 
AIDS dementia complex (ADC), was written by Navia et al. in 1986. At 
that time, progression to AIDS due to an HIV+ diagnosis was almost 
certain, and authors reported that nearly two thirds of autopsied cases 
in their study had signs of dementia that were unexplained by CNS 
opportunistic infection. Cognitive impairment, behavioral changes, and 
motor disturbances were all common features of ADC. For most 
patients, these symptoms began at mild stages and progressed steadily 
over weeks to months until very little cognitive capability remained. At 
end stage disease, it was not uncommon for ADC patients to be 
bedridden, incontinent, and generally unaware of their surroundings.  
 In a companion article concurrently released by Navia et al.,  the 
most frequently observed neuropathological features of ADC were 
reported. Gross cerebral atrophy was the most prominent observation 
across mild, moderate, and severe dementia cases. Other abnormalities 
were white matter pallor and the presence of multinucleated giant cells 
(MGCs), which are produced by fusion of infected macrophages (Sutton 
and Weiss 1966). The majority of pathological observations were in the 
basal ganglia, pons, and other subcortical structures, with the cortex 
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being relatively spared. These symptomatic and neuropathological 
features were repeatedly observed throughout the next decade, along 
with activated microglia, myeloid cell infiltration, synaptodendritic 
damage, and astrocytosis (Petito et al. 1986). It became evident that 
HIV, even in the absence of opportunistic infection or other 
comorbidities, directly caused CNS disease (Price 1996). 
 Throughout this same period, however, manifestations of ADC 
were already beginning to shift with the introduction of the first 
antiretroviral drug azidothymidine (AZT) in 1986. It became 
immediately clear that in addition to dramatically lowering viral load in 
HIV+ individuals (Yarchoan et al. 1986; Fischl et al. 1987), AZT also 
decreased the rate and severity of neurological complications (Yarchoan 
et al. 1987; Schmitt et al. 1988). However, AZT was not an ideal 
therapeutic intervention given its side effect profile and the ability of the 
virus to mutate and eventually escape suppression by the drug (Larder 
and Kemp 1989). 
 To address these issues, scientists developed novel antiretroviral 
agents for use first in combination with and eventually in lieu of AZT. By 
combining several different ARVs with unique mechanisms of action 
targeting viral replication, HIV+ individuals were able to keep viral load 
low, improve immune function, and live longer (Schmit and Weber 
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1997; Brodt et al. 1997). This new standard of care, now known as 
cART, also markedly improved neurological functioning (Ferrando et al. 
1998; Price et al. 1999) and decreased the incidence of ADC (Sacktor 
et al. 2001). Perhaps most importantly, the most severe stages of ADC 
were rarely observed in patients with access to cART (McArthur et al. 
2003).  
 However, it was reported soon after the introduction of cART that 
the rate of ADC did not decline as quickly as rates of other AIDS-defining 
illnesses (Dore et al. 1999), and one report found that among two 
cohorts of patients with advanced infection, rates of neurocognitive 
dysfunction were unchanged by cART (Sacktor et al. 2002). The authors 
concluded that despite marked overall improvements, selected 
neurocognitive deficits remained prevalent.  
 These shifted symptomatic features characterizing the disease in 
the post-cART era predominantly consisted of memory and executive 
function deficits, with less impact on motor skills and verbal processing 
than had been observed in ADC (Heaton et al. 2011). Despite the 
reduced prevalence of severe ADC in particular, these distinct 
impairments have persisted in the decades following cART introduction. 
They form the current classification of HAND and comprise defined 
subsets according to severity (Antinori et al. 2007). Patients diagnosed 
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with asymptomatic neurocognitive impairment (ANI) demonstrate 
impaired performance on neuropsychological testing within at least two 
cognitive domains, but note no interference with everyday functioning, 
whereas a diagnosis of mild neurocognitive disorder (MND) indicates 
similarly impaired testing performance but with added interference in 
daily life. Diagnosis of the most severe form of HAND, HIV-associated 
dementia (HAD), requires that the patient present with moderate-to-
severe impairment within at least two cognitive domains in addition to 
markedly impaired functioning (Rosca et al. 2012; Antinori et al. 2007).        
 Currently, estimates regarding the overall persistence of HAND 
among HIV+ individuals range from 15 – 55% (Sacktor et al. 2016). 
This is controversially high given that up to 70% of these patients fall 
within the ANI category, and it has been suggested that ANI may be 
overestimated (Gisslén et al. 2011). An alternative view, however, is 
that MND is often misdiagnosed as ANI due to patients not recognizing 
the impact their impairments have on daily functioning (Valcour 2013). 
Regardless, ANI patients remain a critical demographic to target 
because these individuals are 2 – 6 times more likely to develop 
moderate or severe forms of HAND versus patients with no impairment 
(Grant et al. 2014a). 
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 Neuropathological features of the disease have also dramatically 
shifted since the advent of cART. In either HIV- vs. HIV+ individuals or 
in individuals with HAND, differences in several cerebrospinal fluid (CSF) 
factors have been identified, including increased immune and cytokine 
activation markers (Kamat et al. 2012; Lyons et al. 2011) and changes 
in factors associated with neuronal damage such as neurofilament light 
chain protein (NFL) and tau (Abdulle et al. 2007; Angel et al. 2012; 
Peluso et al. 2013). However, many of these markers are only relevant 
either for patients with HAD or patients in late stages of immune 
complication (Saylor et al. 2016).   
 Some similarities in post mortem observations exist between 
recent studies and the early reports of Navia et al. 1986, including subtle 
changes in white matter and the presence of HIV-infected perivascular 
macrophages (Brown 2015; Fischer-Smith et al. 2008; Saylor et al. 
2016). Overall, however, HAND patients with viral suppression by cART 
and an absence of other comorbidities look very similar to both 
neurocognitively normal and HIV- controls upon autopsy (Gelman 
2015). This lack of an obvious pathological feature to indicate potential 
therapeutic targets has presented a dilemma for the field, and as yet no 
adjunctive therapies have been approved for use in HAND patients 
(Rosca et al. 2012; Saylor et al. 2016). 
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 As an added complexity in the navigation of this changing disease, 
increased lifespan afforded by cART (Lai et al. 2006) means the average 
age of HIV+ individuals is increasing. Currently over half of HIV+ 
individuals in the United States are over 50 years of age, and many of 
these patients have been living with HIV for decades (Valcour 2013). 
Thus, physicians and scientists have the novel task of understanding 
effects of both aging and prolonged duration of infection on cognitive 
functioning. Some studies have indicated that aging may not exacerbate 
HAND symptoms (Milanini et al. 2017; Vance et al. 2016), but potential 
confounds and inconsistent results have left the individual contributions 
of aging and HIV difficult to resolve (Hellmuth et al. 2014).  
 Abnormal aging is also a concern, with particular attention paid to 
whether HIV+ individuals are more likely to develop Alzheimer’s Disease 
(AD). Of concern, the genetic risk factor for AD ApoE є4 is also predictive 
of poorer cognition and increased brain atrophy in HIV+ patients over 
60, indicating the possibility of mechanistic overlap between AD and 
HAND (Panos et al. 2013; Wendelken et al. 2016). However, the data 
regarding the similarities and differences between the two diseases have 
been mixed. The following section includes a detailed discussion of AD-
like symptoms, biomarkers, and pathology among HIV+ individuals.  
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Common features of Alzheimer’s Disease and HAND: a focus on 
amyloid precursor protein 
 With an aging HIV+ population, HAND and AD are now emerging 
in an overlapping demographic of men and women over 60. HAND in its 
current form shares symptoms in common with AD including personality 
changes, forgetfulness, and attention difficulties (Meehan and Brush 
2001). In some cases, these similarities impede the ability of physicians 
to distinguish AD from HAND (Xu and Ikezu 2008; Szirony 1999). 
  
Soluble markers in cerebrospinal fluid and plasma 
 One diagnostic strategy is to measure soluble factors in the CSF 
that can serve as unique disease biomarkers. The defining CSF 
biomarker of AD is decreased concentrations of the soluble peptide 
amyloid-β 42 (Aβ42) (Dickerson et al. 2013; Blennow et al. 2015), and 
it has been suggested that these changes are specific to AD and can be 
used to distinguish from HAND (Ances et al. 2012; Steinbrink et al. 
2013; Mäkitalo et al. 2015). In fact, one study reported increased levels 
of CSF Aβ42 in HIV+ patients as compared to HIV- controls (Peluso et 
al. 2013). However, three other studies (Brew et al. 2005; Clifford et al. 
2009b; Krut et al. 2013) identified a pattern of CSF Aβ42 decrease in 
HIV+ individuals similar to that seen in AD patients, implying both less 
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potential utility as a unique biomarker as well as possible overlapping 
mechanistic features of the two diseases. Importantly, decreases were 
observed even in patients on cART, and they were specific to Aβ42 while 
other AD biomarkers such as phosphorylated tau and total tau were 
unchanged. These contradictory results have made it difficult to clearly 
identify biomarkers of HAND as well as to determine whether 
mechanisms involving Aβ42 are relevant for HAND neuropathogenesis.  
  
Amyloid plaque formation and the role of β-amyloid cleaving enzyme in 
Alzheimer’s Disease 
 In AD, CSF Aβ42 concentration is anticorrelated with Aβ42-related 
pathology in the brain, characterized by amyloid deposition. Amyloid 
deposition is a hallmark feature of AD and describes the accumulation 
of dense amyloid plaques in the extracellular space of hippocampus, 
cortex, and other regions depending on progression of disease (Fagan 
et al. 2006; Roe et al. 2013).  
 Amyloid plaques are formed through proteolytic processing of 
amyloid precursor protein (APP). Under normal physiological conditions, 
APP is trafficked through the secretory pathway to the cell surface, 
where in its full-length form it serves a variety of functions involving 
cell-cell adhesion and synaptic regulation (Müller et al. 2017). It is also 
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sequentially cleaved by the α-secretase a disintegrin and 
metalloproteinase domain-containing protein (ADAM10) (Lammich et al. 
1999) and the γ-secretase presenilin 1 (PS-1) (Selkoe and Wolfe 2000), 
resulting in the production of cleavage products with additional unique 
roles in cellular function. One of these cleavage products in particular, 
soluble APPα (sAPPα), has been identified as a neuroprotective factor 
through multiple downstream mechanisms (Obregon et al. 2012; 
Milosch et al. 2014; Furukawa and Mattson 1998). APP is also 
constitutively endocytosed, and in endosomes it is cleaved by the β-
secretase β-site amyloid precursor protein cleaving enzyme 1 (BACE1) 
to form sAPPβ and C-terminal fragment-β (CTFβ) (Kandalepas and 
Vassar 2014). CTFβ is then cleaved by PS-1 to generate an APP 
intracellular domain (AICD) fragment and the Aβ42 or Aβ40 monomer. 
Aβ42 monomers readily oligomerize and can eventually form dense 
fibrils and amyloid plaques. Although the generation of Aβ42 monomers 
is not abnormal, the observation of plaque formation is strictly seen in 
pathological cases and forms one of the major defining features of AD 
(Blennow et al. 2015). Critically, however, plaque formation is not 
necessarily correlated with cognitive impairment in AD (Perrin et al. 
2009), and stronger correlations are observed when comparing 
cognition with the accumulation of Aβ42 oligomers at the synaptic cleft 
 12
(Haass and Selkoe 2007). These and other observations in animal 
models suggest that toxicity may be driven by the oligomeric Aβ species 
rather than plaques themselves (Kayed and Lasagna-Reeves 2013; 
Sengupta et al. 2016).   
 Expression of BACE1 protein is increased by approximately two-
fold in AD patient brains (Fukumoto et al. 2002; Holsinger et al. 2002; 
Yang et al. 2003; Johnston et al. 2005), while expression of ADAM10 is 
decreased in both brain and CSF (Colciaghi et al. 2002; Bernstein et al. 
2003; Olsson et al. 2003; Fellgiebel et al. 2009). This imbalance drives 
APP processing toward the amyloidogenic rather than the non-
amyloidogenic pathway in AD, resulting in decreased levels of 
neuroprotective sAPPα (Almkvist et al. 1997; Lannfelt et al. 1995) as 
well as increased β-amyloid oligomers and the formation of plaques. 
Shifts in secretase expression and activity may play a causal role in 
cognitive impairment. Indeed, one genetic mutation predicting early 
onset AD is a change in the amino acid sequence of APP that confers 
higher affinity for BACE1 (Citron et al. 1992). Genetic loss of BACE1 in 
animal models essentially abolishes Aβ production (McConlogue et al. 
2007), and in several rodent models of AD either genetic or 
pharmacologic BACE1 inhibition improves synapse function and memory 
(Ohno et al. 2004; Singer et al. 2005; Fukumoto et al. 2010; Chang et 
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al. 2011; Devi et al. 2015). Based on these studies and others, BACE1 
inhibitors have been developed by several pharmaceutical companies 
and are currently in phase II and III clinical trials to assess efficacy in 
treating AD patients (Yan and Vassar 2014; Ghosh and Tang 2015). 
 Whether similar BACE1 upregulation or BACE1-dependent 
impairments are present in HAND or animal models of HIV is not known. 
In vitro studies suggest that the viral protein trans-activator of 
transcription (tat) can stimulate BACE1 colocalization with APP in the 
endolysosome and increase its proteolytic activity (Chen et al. 2013; 
Kim et al. 2013), and viral protein glycoprotein 120 (gp120) can 
increase BACE1 transcription (Bae et al. 2014). However, relevance of 
these particular mechanisms in mixed neuroglial environments or in vivo 
remains unclear.  
 
Amyloid Precursor Protein Processing in HAND  
 Despite the lack of research focused on a specific role for BACE1 
in HAND, many studies have attempted to address whether pathological 
APP processing is present in patients. Reports have conclusively 
identified diffuse amyloid plaques or other amyloid pathology in HIV+ 
patients prior to the availability of cART (Raja et al. 1997; Esiri et al. 
1998; Izycka-Swieszewska et al. 2000; Rempel and Pulliam 2005; 
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Achim et al. 2009). In cohorts that included patients taking cART, 
amyloid pathology has also been observed (Green et al. 2005; 
Soontornniyomkij et al. 2012; Levine et al. 2016), and in one study 
patients with access to cART actually had increased amyloid deposition 
as compared to patients in the pre-cART era (Green et al. 2005). 
However, this could be due to several factors, including the 
parsimonious explanation that patients taking cART live longer following 
seroconversion.  
 Although these post mortem studies converge on agreement that 
altered APP processing is present in HIV+ individuals, it remains unclear 
A) whether APP pathology is a feature of HAND or of HIV in general, B) 
whether the observed accumulation represents amyloid, full-length APP, 
or an intermediate species such as Aβ42 oligomers, and C) whether the 
observed accumulation is extracellular (as observed in AD) or 
intracellular. Although very few data exist to address the first two points, 
current evidence from analysis of brain tissue samples suggests that 
intracellular vs extracellular pathology is more commonly observed 
(Green et al. 2005; Achim et al. 2009). These findings are corroborated 
by a series of positron emission tomography (PET) scan experiments 
using Pittsburgh compound B ([11C] PiB) to specifically recognize fibrillar 
amyloid deposits in the extracellular space. Three of such studies (Ances 
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et al. 2010; Ances et al. 2012; Ortega and Ances 2014) found no 
evidence of extracellular deposition in HIV or HAND specifically, even in 
older patient populations.  
 Hence, the difficulty in determining the potential role of APP 
processing in HAND lies in its unique presentation. Ample evidence 
suggests that APP processing differs in HIV+ individuals versus HIV- 
controls; however, neither CSF nor parenchymal observations mimic 
those characteristic of AD. A more detailed characterization of the 
specific APP pathology associated with HIV and HAND is needed in order 
to assess the precise mechanisms implicated in AD that may also be 
relevant in HAND. A better understanding of this overlap has potential 
to facilitate A) distinction between the two diseases when diagnosing 
older patients with HIV, B) rational drug design for adjunctive therapies 
in HAND, and C) determination of disease-causing pathological features 
as distinct from epiphenomena. This last potential benefit is often 
underappreciated but should not be overlooked; if scientists are able to 
more precisely identify common pathology across neurodegenerative 
diseases with similar symptoms, there will be a higher likelihood of 
identifying features directly related to those symptoms. Critically, this 
approach may accelerate advances in AD as well as in HAND. 
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 Although a more precise clarification of APP pathology in HAND 
will be useful, it is also important to note that additional APP species 
rather than amyloid plaques per se may mediate toxicity in AD (Kayed 
and Lasagna-Reeves 2013). Thus, HAND neuropathogenesis may still 
be related to amyloidogenic processing of APP even if extracellular 
plaques are not formed in HIV+ patient brains.     
 
HIV or antiretrovirals: which is responsible for HAND 
persistence?  
 To explain the persistence of HAND despite viral suppression with 
cART (Saylor et al. 2016), two distinct theories have emerged: either A) 
CNS penetrance and/or efficacy of antiretroviral drugs (ARVs) is not high 
enough to sufficiently reduce viral load in the brain, or B) ARVs 
themselves contribute to the development of HAND (Etherton et al. 
2015). Given that these two possibilities have exactly opposite 
implications for how to set new therapeutic goals, identifying the true 
cause of HAND persistence has been a high priority over the past 
decade.  
 
Evidence for the role of HIV 
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 The most convincing point in support of a role for HIV rather than 
ARVs in HAND persistence is that for most ARVs, with the exception of 
efavirenz (Avery et al. 2013) and dolutegravir (Letendre et al. 2014), 
concentrations in CSF are substantially lower than those measured in 
plasma (Best et al. 2009; Best et al. 2012; Eisfeld et al. 2013). 
Moreover, the primary cells in the brain responsible for viral replication 
are macrophages, and effects of ARVs on HIV in macrophages are not 
as pronounced as effects on peripheral T cells (Aquaro et al. 2002). 
Finally, one study of 53 patients found that in some cases HIV in the 
CSF developed resistance to ARVs independently from virus in the 
plasma (Cunningham et al. 2000). Perhaps due to one or more of these 
factors, viral RNA has been identified in CSF even when plasma viral 
loads are undetectable (Edén et al. 2010; Canestri et al. 2010; Peluso 
et al. 2012), a phenomenon termed viral escape. In cases of high viral 
load in the brain, HIV may cause neurological impairments through 
direct effects of viral proteins on neurons, alterations in glial function 
with indirect effects on neurons, or a combination of both routes (Kaul 
2008; Kaul and Lipton 2006; Kovalevich and Langford 2012).  
 HIV does not directly infect neurons, but factors shed from the 
virus may still affect neurons through interactions with surface receptor 
proteins (Kaul et al. 2001). HIV canonically enters cells by interaction 
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with CD4 as well as either the CXCR4 or CCR5 chemokine receptor; 
these chemokine receptors are expressed in neurons (Asensio and 
Campbell 1999), and in vitro evidence suggests they may mediate 
neurotoxicity induced by HIV (Chen et al. 2002; Kaul and Lipton 1999). 
Several viral proteins cause neuronal damage in vitro including tat (New 
et al. 1997), gp120 (Brenneman et al. 1988; Kaul et al. 2001), and nef 
(Koedel et al. 1999). Neurotoxic potential of these proteins persists in 
primary neuronal cultures without glia (Meucci et al. 1998) as well as in 
neuroblastoma cell lines (Hesselgesser et al. 1998), indicating that 
direct effects on neurons are a possible mediator of neuronal damage 
induced by HIV.  
 However, ample evidence suggests that when the neuronal 
environment better reflects the brain by including glial populations, HIV-
induced neurotoxicity is primarily mediated by other cell types (Kaul et 
al. 2001). Macrophages in particular play a critical role, as they sustain 
productive infection by HIV beginning soon after seroconversion (Ho et 
al. 1985; Koenig et al. 1986). In 1990, scientists observed that in vitro 
these infected myeloid cells secrete factors that induce potent 
neurotoxicity (Giulian et al. 1990). Moreover, direct stimulation of 
uninfected myeloid cells with gp120 was also sufficient to induce release 
of neurotoxins (Giulian et al. 1993), indicating that effects of viral 
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proteins in many in vitro experiments may be explained by glial 
involvement. Indeed, several later studies confirmed that macrophages 
were a key driver of HIV-induced neurotoxicity under various 
experimental paradigms and through multiple downstream mechanisms 
(Kaul and Lipton 1999; Viviani et al. 2001; Medders et al. 2010; Festa 
et al. 2015). Astrocytes also make important contributions to the 
neurotoxicity of HIV both in vivo and in vitro (Genis et al. 1992; 
Vázquez-Santiago et al. 2014).   
 
Evidence for the role of antiretroviral drugs 
 Depending on their mechanism of action, ARVs can be divided into 
six classes: nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors 
(PIs), integrase strand transfer inhibitors (INSTIs), fusion inhibitors 
(FIs), and entry inhibitors (EIs). The Department of Health and Human 
Services (DHHS) current recommends that frontline treatment for HIV 
include two NRTIs in combination with a PI or an INSTI (DHHS 2016a). 
This particular regimen is not optimally effective for all patients nor 
available across the globe to all HIV+ individuals, and therefore all 
classes are still routinely prescribed depending on the circumstances.   
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 Ample evidence also suggests that ARVs may contribute to HAND 
neuropathogenesis. In in vitro and animal studies, ARVs from various 
drug classes can induce mitochondrial dysfunction, ER stress, and 
oxidative stress, ultimately leading to synaptodendritic damage and 
neuronal death (Akay et al. 2014; Brown et al. 2014; Robertson et al. 
2012b; Vivithanaporn et al. 2016; Gannon et al. 2017).  
  The early NRTIs, and in particular the first drug introduced to 
treat HIV, zidovudine (AZT), induced potent mitochondrial toxicity after 
chronic exposure (Lewis and Dalakas 1995). This potential may be due 
to an inhibitory effect of nucleoside analogues on the γ-subunit of DNA 
polymerase (Côté et al. 2002; Apostolova et al. 2011), as several other 
NRTIs have since been found to damage mitochondrial DNA as well 
(Dalakas 2001). Indeed, in one study the NRTI efavirenz caused a loss 
of ATP and depolarization and fragmentation of mitochondria in both 
primary neurons and a neuroblastoma cell line (Purnell and Fox 2014). 
Mitochondrial toxicity has also been observed across cell types including 
neurons with both NNRTIs and PIs, although the mechanisms are 
unclear (Apostolova et al. 2011). Interestingly, however, in one 
experiment probing both mitochondrial damage and neurotoxic 
potential of ARVs across classes, the effects of ARVs on mitochondrial 
respiration were not related to neurotoxic potential (Robertson et al. 
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2012b). This indicates that at least for some ARVs, damage occurs 
through additional mitochondria-independent pathways.  
 An additional mechanism of neurotoxicity induced by ARVs may 
be endoplasmic reticulum (ER) stress, resulting from an accumulation 
of misfolded proteins and causing activation of the unfolded protein 
response (UPR). In one recent report, the NRTI efavirenz caused 
activation of UPR signaling proteins protein kinase R-like endoplasmic 
reticulum kinase (PERK) and inositol-requiring enzyme 1 (IRE1) in brain 
endothelial cells (Bertrand and Toborek 2015), indicating a potential 
mechanism by which ARVs may disrupt the blood-brain barrier (BBB). 
The effects of PIs on ER stress have also been the subject of 
investigation given that PIs ritonavir (André et al. 1998), saquinavir 
(Pajonk et al. 2002), and nelfinavir (Hamel et al. 2006) can directly 
inhibit the proteasome causing ER protein accumulation. Our previous 
work has demonstrated that ritonavir leads to PERK activation both in 
vivo and in vitro, resulting in increased BACE1 expression and neuronal 
damage (Gannon et al. 2017). Potential relevance of this pathway in 
patients is highlighted by our earlier work demonstrating UPR activation 
in post mortem HIV+ brains (Lindl et al. 2007; Akay et al. 2012), 
although these results cannot distinguish between effects of ARVs and 
possible effects of HIV itself on ER stress.  
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 ARVs across classes can increase production of reactive oxygen 
species (ROS) leading to oxidative stress in many cell types. This 
phenomenon has received most attention in the periphery due to its role 
in many of the common side effects associated with ARVs (Elias et al. 
2013; Ivanov et al. 2016). In HIV+ patients, indicators of oxidative 
stress in plasma are increased by HIV itself and further increased by 
ARVs, including PIs in particular (Ngondi et al. 2006; da Cunha et al. 
2013). Studies addressing oxidative stress in the brain specifically are 
less abundant, but one report demonstrated that the NRTI efavirenz 
increased ROS in a neuroblastoma cell line, which was associated with 
increases in BACE1 expression and activity (Brown et al. 2014). In 
addition, we have shown that PIs ritonavir and saquinavir potently 
increase ROS in primary neuronal cultures and that alleviation of 
oxidative stress with monomethyl fumarate (MMF) is protective against 
PI-induced neuronal damage. In the same study, relevant combinations 
of ARVs including a PI induced neuronal damage and neuronal loss in 
both non-human primates and rats (Akay et al. 2014), indicating ability 
of ARVs to injure neurons in vivo regardless of HIV infection.  
 Although in vitro and animal studies have provided valuable 
insights into the possible mechanisms of ARV-induced neurotoxicity, the 
most powerful evidence in support of neurotoxic potential for cART is 
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observed in the clinic. Indeed, neuropsychiatric side effects are 
associated with ARVs across several classes, including NRTIs lamivudine 
(Song et al.) and abacavir (Colebunders et al. 2002; Palacin et al. 2006; 
Foster et al. 2004), NNRTIs efavirenz (Mollan et al. 2014; Clifford et al. 
2009a; Ma et al. 2016; Arendt et al. 2007) and nevirapine (Wise et al. 
2002; Morlese et al. 2002); and INSTIs raltegravir (Harris et al. 2008; 
Eiden et al. 2011; Gray and Young 2009) and dolutegravir (Kheloufi et 
al. 2015; Hoffmann et al. 2017). In one surprising study, patients taking 
either NRTIs, NNRTIs, PIs, or a combination of all three drug classes 
improved their psychological testing scores following temporary ART 
discontinuation (Robertson et al. 2010). One important caveat in the 
interpretation of these studies is that neuropsychiatric side effects of 
ARVs may be due to indirect effects on the brain caused by peripheral 
toxicities (Troya and Bascuñana 2016), and therefore human data alone 
cannot directly implicate ARV effects on neurons. Also of critical note is 
that these studies do not negate the overwhelming benefits of cART nor 
indicate that patients should discontinue medication under any 
circumstances (Saylor et al. 2016). They should, however, provide 
potential cause for reevaluation of treatment strategies with the goal of 
maintaining optimal cognitive function.  
  
 24
Barriers to identifying drug regimens that minimize cognitive 
impairment 
 Scientists are eager to determine whether HIV or ARVs is the 
primary contributor to HAND in order to better understand disease 
persistence, and clinicians have the added urgency of needing to provide 
the optimal regimens to their patients. In an attempt to elegantly 
address both of these needs, clinicians developed a measure of how 
effectively different ARVs can access the brain, which is called the CNS 
penetration effectiveness score (CPE) (Letendre et al. 2008). 
Unfortunately, however, studies comparing CPE scores of drug regimens 
with neurocognitive functioning have not provided clarity regarding 
whether or not high drug concentrations in the CNS are beneficial. At 
least three studies have reported improved cognition with increased CPE 
score (Tozzi et al. 2009; Smurzynski et al. 2011; Carvalhal et al. 2016), 
indicating that in these patients cognitive impairment may have been 
caused by HIV rather than ARVs. In contrast, however, two studies 
reported improved cognition associated with lower CPE regimens (Marra 
et al. 2009; Caniglia et al. 2014), and Caniglia et al. 2014 specifically 
identified an increased risk of HAD as CPE score increased. Finally, two 
additional experiments yielded no evidence of a significant relationship 
between CPE score and cognitive functioning (Robertson et al. 2012a; 
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Ellis et al. 2014). Given the diversity of these results, in clinical practice 
it is not advised to consider CPE score when designing an ART regimen 
(Saylor et al. 2016). 
 One possible reason for the mixed evidence gathered from CPE 
studies is likely to be heterogeneity of ARVs both within and between 
classes. Because no such drugs exist that are identical with the 
exception of their CPE score, effects of CNS penetrance cannot truly be 
compared directly in human subjects. Moreover, presentation of HAND 
is heterogeneous as well. The ideal tests for screening and diagnosis of 
HAND both in research and in clinical practice are not yet standardized 
and continue to produce highly variable data regarding nature and 
severity of cognitive symptoms, particularly during longitudinal follow-
up (Kamminga et al. 2013; Kamminga et al. 2017b; Kamminga et al. 
2017a). In addition to these obstacles, however, perhaps a clear 
consensus cannot be reached because both HIV and ARVs play 
important additive or synergistic roles in the persistence of HAND 
(Sanchez and Kaul 2017).    
 
A third possibility: combined contributions 
 The data presented in this dissertation suggest that both HIV and 
ARVs may contribute to HAND through distinct mechanisms. This may 
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partially explain why data in human patients have been mixed, and 
increasing CNS penetrance of ART regimens does not consistently 
improve or impair cognitive function. Because of this complexity, the 
best clinical goals may not be related to increasing or decreasing CNS 
ARV concentrations, but rather designing therapeutic regimens with low 
neuropsychiatric side effect profiles despite high viral suppression in the 
CSF. 
 
Modeling HIV with a focus on NMDA receptors 
 Both macrophages and astrocytes are likely to play a key role in 
HAND neuropathogenesis given that they are susceptible to HIV 
infection and are required for regulation of extracellular glutamate 
concentrations (Vázquez-Santiago et al. 2014). Indeed, patients with 
HAD have increased CSF glutamate concentrations that are correlated 
with cognitive impairment (Ferrarese et al. 1997; Ferrarese et al. 2001). 
In an animal model of HIV, researchers identified disruptions in 
astrocytic glutamate reuptake due to effects of HIV on microglia as a 
mediator of neuronal damage (Moidunny et al. 2016). Direct glutamate 
release and/or impaired reuptake from HIV-infected macrophages also 
causes neuronal damage in vitro (Jiang et al. 2001) and impaired 
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hippocampal synaptic plasticity and memory deficits in an animal model 
of HIV encephalitis (Zink et al. 2002).  
  
 
The multiple paths to NMDA receptor activation in HAND 
 Several glutamate receptors are expressed in neurons including 
metabotropic receptors (mGluRs 1-8) and ionotropic N-methyl-d-
aspartate receptors (NMDARs), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs), and kainate receptors. 
Several of these receptor subtypes have been implicated in disease 
pathogenesis (Nicoletti et al. 2011; Traynelis et al. 2010), but evidence 
suggests a more prominent role for NMDARs in neurodegenerative 
mechanisms due to their mediation of excitotoxicity (Lipton and 
Rosenberg 1994; Mehta et al. 2013; Carvajal et al. 2016; Kocahan and 
Doğan 2017). Indeed, excitotoxic damage downstream of NMDAR 
activation is another common feature of AD (Kocahan and Doğan 2017) 
that may also be implicated in HAND.    
 In HIV+ patient post mortem brain samples, NMDAR subunit-
encoding genes are downregulated in frontal cortex along with other 
genes involved in synaptic signaling and transmission (Masliah et al. 
2004); this may indicate a negative feedback mechanism to regulate 
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excitatory post-synaptic potentials during repeated NMDAR stimulation. 
Moreover, in an animal model of HIV, neuronal damage induced by 
increased extracellular glutamate concentration was dependent upon 
NMDARs (Moidunny et al. 2016).  
 In an early in vitro model of HIV in which human myeloid cells 
were infected and the conditioned media was used to treat primary chick 
ciliary neurons, NMDAR activation was required for neurotoxicity 
(Giulian et al. 1990). Although in this circumstance the NMDAR 
activation was likely due to glutamate release by infected cells (Jiang et 
al. 2001), it is important to note that NMDARs can be activated by 
additional secreted factors, such as chemokines, or by viral proteins 
directly. One of the first studies to suggest this possibility showed that 
gp120-induced neuronal damage was accompanied by increased 
intracellular calcium concentrations and was prevented by a calcium 
channel antagonist (Dreyer et al. 1990). Later experiments implicated 
NMDARs more directly in gp120-induced calcium influx and toxicity 
(Lannuzel et al. 1995) and demonstrated that gp120 acts as an NMDAR 
agonist by occupying the glycine binding site (Fontana et al. 1997). 
Ability of gp120 to bind NMDARs and increase intracellular calcium 
concentration in hippocampal cells was selectively enhanced by 
extrasynaptic NMDAR2B receptor subunits (Zhou et al. 2016), which 
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play a particularly critical role in excitotoxic disease mechanisms 
(Bading 2017). Synaptic damage caused by exposure to the viral protein 
tat can also be reversed by inhibition of NMDA receptors (Shin et al. 
2012), and NMDA antagonists are protective in rodent models of HIV 
involving either gp120 or tat (Mucke et al. 1995; Anderson et al. 2004; 
Nakanishi et al. 2016). Considered together, these studies indicate that 
regardless of whether neurotoxicity is caused by direct interactions with 
viral particles or glutamate imbalance due to glial infection/activation, 
NMDARs are likely to play a role. Unfortunately, although NMDARs 
received attention in the past as a potential therapeutic target in HAND, 
failed phase III trials of the NMDAR antagonist memantine has 
decreased momentum for this approach in recent years (Schifitto et al. 
2007; Zhao et al. 2010). 
 
An in vitro model of HIV-induced neurotoxicity: critical roles for 
glutamate and NMDAR signaling 
 The two main challenges in designing a cell culture model relevant 
to HAND are that A) HIV does not infect neurons, and B) HIV does not 
infect non-human cells. The first point can be seen as an opportunity 
rather than an obstacle, however, because macrophages, which do 
sustain productive viral infection in vivo (Rappaport and Volsky 2015), 
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are more readily available from human donors. As discussed above, 
HIV-associated effects on neurons are likely to at least in part be 
mediated indirectly through macrophage infection (Kaul et al. 2005); 
hence, scientists are able to use macrophages in order to model HIV-
induced neurotoxicity.   
 This type of model was created in 1990 by Giulian et al., who 
infected human macrophages with isolated strains of T-cell-propagated 
HIV and periodically collected conditioned media from the infected cell 
cultures. This media was then used to treat primary neurons isolated 
from chickens. Treatment caused severe neuron loss that was entirely 
prevented by inhibition of NMDARs but unaffected by inhibition of 
AMPARs or kainate receptors. The same group subsequently observed 
that gp120-induced neuronal damage could be similarly blocked by 
selective NMDAR inhibition (Giulian et al. 1993). 
 The model was later adapted into the HIV-infected monocyte-
derived macrophage (HIV/MDM) model used for experiments presented 
in this dissertation (Chen et al. 2002). In this model, monocytes are 
isolated from blood samples collected from healthy human donors and 
are differentiated into macrophages in culture. Isolated HIV strains are 
used to infect these macrophages, and conditioned media is collected 
over a period of several days. The conditioned media can be used to 
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treat neurons from either cell lines or primary isolations of multiple 
species including rats, mice, and humans (Chen et al. 2002; O’Donnell 
et al. 2006). Careful characterization of this model has revealed that 
neurotoxicity is mediated specifically by NMDAR2A and NMDAR2B 
subtypes, and that glutamate in the conditioned media is the primary 
but not the sole factor leading to cell loss (O’Donnell et al. 2006).  
 
The daunting diversity of mechanisms in HAND 
 On the surface, it would seem that determining mechanistic 
responsibility for HAND should be a relatively simple task. Unlike in 
idiopathic diseases such as AD, for instance, the cause is essentially 
known: it must be either HIV or ARVs. This determination is 
complicated, however, by the opinion proposed herein and elsewhere 
that causes are multifactorial and may differ among patients.  
 In the following chapter, the role of HIV will be addressed, with a 
specific focus on mechanistic overlap between HAND and AD. Although 
the data thus far indicate that neuropathogenesis in HAND is distinct 
from AD in terms of APP processing overall, it remains critical to identify 
the precise features that may be shared. This would not only accelerate 
progress in HAND by utilizing the breadth of information gathered from 
decades of AD research, but also would provide valuable insights into 
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common pathways of neurodegeneration that could be targeted across 
diseases.  
 In a subsequent chapter, the potential contributions of ARVs to 
HAND are addressed in vitro. Here, the attempt to identify a cause of 
HAND persistence is further complicated by the diversity of ARV classes 
as well as the diversity of drugs within a single class. It is likely that 
mechanisms contributing to neurotoxicity of one drug may be not be 
relevant to other ARVs. 
 Because of drug diversity as well as variability among patients 
with HIV, it may not be feasible to define a single rationale for HAND 
persistence. Instead, scientists can hope to provide doctors with 
increasingly powerful tools that will aid in the personalization of cART 
regimen design. However, those mechanisms that do have overlapping 
relevance either across ARV classes, across patients with inconsistent 
serum or CSF profiles, or across diseases are critical to identify because 
they will provide the most promising therapeutic targets.  
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CHAPTER 2: BACE1 MEDIATES HIV-ASSOCIATED 
AND EXCITOTOXIC NEURONAL DAMAGE THROUGH 
AN APP-DEPENDENT MECHANISM 
Anna L Stern, Patrick  J Gannon, Alan C Yee, Jessica Phan, Benjamin B 
Gelman, Dennis L Kolson, and Kelly L Jordan-Sciutto 
 
Abstract  
 HIV-associated neurocognitive disorder (HAND) has been 
reported to share symptoms and neuropathological features with 
Alzheimer’s Disease (AD), which is characterized by amyloid-β (Aβ) 
plaques in patient brains. Plaques are formed by aggregation of Aβ 
oligomers, which may be the toxic species in AD pathogenesis, and 
oligomers are generated by cleavage of amyloid precursor protein (APP) 
by β-site amyloid precursor protein cleaving enzyme 1 (BACE1). BACE1 
inhibitors reverse neuronal loss and cognitive decline in animal models 
of AD. Although some studies have also found evidence of altered APP 
processing in HIV+ patients, it is unknown whether increased BACE1 or 
Aβ oligomers is a feature of HAND. Moreover, it is unknown whether 
BACE1 or APP is implicated in the excitotoxic, NMDA receptor-dependent 
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component of HIV-associated neurotoxicity in vitro. Thus, we 
hypothesize that HIV-associated neurotoxicity is mediated by NMDAR-
dependent elevation of BACE1 and subsequent altered processing of 
APP. Supporting this, we observed elevated levels of BACE1 and Aβ 
oligomers in CNS of HIV+ patients.  In a model of HIV-associated 
neurotoxicity in which primary rat neurons are treated with 
supernatants from HIV-infected monocyte-derived macrophages 
(HIV/MDMs), we observed NMDAR-dependent elevation of BACE1 
protein levels. NMDA treatment also increased BACE1, and both 
pharmacological BACE1 inhibition and genetic loss of APP were partially 
neuroprotective. Moreover, in APP-/- neurons, toxicity was BACE1-
independent, indicating that the role of BACE1 is directly related to 
cleavage of APP. These findings suggest that increased BACE1 and 
resultant Aβ oligomer production may contribute to HIV-associated 
neuropathology, and inhibition of BACE1 may have therapeutic potential 
in HAND.   
 
Significance 
 HIV-associated neurocognitive disorder (HAND) is a range of 
cognitive impairments affecting approximately 50% of HIV+ individuals. 
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The cause of HAND is unknown, but evidence suggests that HIV-infected 
macrophage infiltration into the brain may cause neuronal damage. 
Herein, we show that neurons treated with conditioned media from HIV-
infected macrophages have increased expression of β-site amyloid 
precursor protein cleaving enzyme 1 (BACE1), a protein implicated in 
Alzheimer’s Disease (AD) pathogenesis. Moreover, inhibition of BACE1 
prevented neuron loss due to conditioned media exposure, but it had no 
effect on HIV-associated neurotoxicity in neurons lacking its cleavage 
target amyloid precursor protein (APP). We also observed increased 
BACE1 expression in HIV+ patient brain tissue, confirming the potential 
relevance of BACE1 as a therapeutic target in HAND.  
  
Introduction 
 HIV-associated neurocognitive disorder (HAND), which persists in 
15% - 55% of HIV+ individuals despite viral suppression by ART, is a 
constellation of cognitive, behavioral, and motor impairments (Sacktor 
et al. 2016). HAND has some clinical (Sacktor and Robertson 2014) and 
pathological (Clifford et al. 2009b; Borjabad and Volsky 2012; Levine et 
al. 2013; Ortega and Ances 2014) features in common with Alzheimer’s 
Disease (AD), and in an aging HIV+ population (Valcour 2013) it is 
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increasingly difficult to distinguish AD from the combined effects of age 
and HIV (Xu and Ikezu 2008). Understanding the common pathways 
involved in neuropathology will maximize the efficacy of treatment.  
 In AD, increased amyloid precursor protein (APP) cleavage by the 
β-secretase β-site amyloid precursor protein cleaving enzyme-1 
(BACE1) leads to overproduction of amyloid-β (Aβ) peptides (MacLeod 
et al. 2015). Aβ peptides can oligomerize and ultimately form 
extracellular aggregates called plaques (Trojanowski et al. 1995). 
Importantly, although extracellular plaques are a defining feature of AD, 
Aβ oligomers are more likely to be the neuropathogenic species 
(Sengupta et al. 2016; Kayed and Lasagna-Reeves 2013). In HAND, 
evidence of a role for amyloid is more mixed, but the majority of studies 
(Esiri et al. 1998; Rempel and Pulliam 2005; Achim et al. 2009; Clifford 
et al. 2009b; Brew et al. 2005) indicate that there is altered APP 
processing and metabolism of some form, even in patients on effective 
ART regimens (Green et al. 2005; Soontornniyomkij et al. 2012). Unlike 
in AD, however, ART-treated HAND patients do not form extracellular 
plaques. Rather, evidence suggests diffuse intracellular accumulation of 
either full-length APP, Aβ, or oligomers (Ortega and Ances 2014; Xu and 
Ikezu 2008). Despite its proposed role in AD neuropathogenesis 
(Sengupta et al. 2016; Kayed and Lasagna-Reeves 2013), a lack of 
 37
antibody specificity and wide variation across study designs have made 
it difficult thus far to determine whether oligomeric Aβ specifically is 
altered in HAND.  
 BACE1 is elevated in AD brains (Yang et al. 2003; Johnston et al. 
2005), and BACE1 inhibition effectively decreases plaque burden and 
improves cognition in animal models of AD (Singer et al. 2005; Ohno et 
al. 2004; Chang et al. 2011). Evidence from in vitro experiments in 
primary rodent neurons shows that BACE1 activity and localization are 
also affected by treatment with HIV proteins trans-activator of 
transcription (tat) and glycoprotein 120 (gp120) (Chen et al. 2013; Kim 
et al. 2013; Bae et al. 2014).  However, it remains unknown what role 
BACE1 plays in HIV-associated neurotoxicity and neuropathogenesis. 
 Macrophages sustain productive viral infection in HIV patient 
brains (Petito et al. 1986; Koenig et al. 1986), and infected 
macrophages may mediate HIV-associated neurotoxicity by secreting 
factors that include viral proteins, chemokines, and glutamate (Kaul 
2008). Glutamate release in particular has been linked to neuronal 
damage and cognitive dysfunction in HIV both in vivo and in vitro (Jiang 
et al. 2001; Zink et al. 2002). Similarly to AD pathology (Mehta et al. 
2013),  in vitro evidence suggests that glutamate may cause neuronal 
damage in HIV through NMDA receptor (NMDAR)-dependent 
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mechanisms of excitotoxicity (Giulian et al. 1990; Chen et al. 2002; 
O’Donnell et al. 2006). Consequently, we employed a previously 
developed and well-characterized in vitro model of HIV-associated 
neurotoxicity (Chen et al. 2002; O’Donnell et al. 2006) in which cultured 
rat neurons are exposed to supernatants collected from HIV-infected 
human monocyte-derived macrophages (HIV/MDMs). In this model, 
neurotoxic injury induced by HIV/MDM supernatants is entirely 
dependent on NMDAR activation (Giulian et al. 1990; Jiang et al. 2001; 
Chen et al. 2002; O’Donnell et al. 2006). 
 Based on the similarities observed thus far between AD and HAND 
in relation to amyloid metabolism (Ortega and Ances 2014), we 
hypothesized that Aβ oligomers and BACE1 protein levels are increased 
in HAND patient brains. Moreover, we hypothesized that in vitro 
neurotoxicity induced by HIV/MDM supernatants is dependent upon 
NMDAR-mediated upregulation of BACE1 and a resultant increase in 
amyloidogenic APP processing.  
 
Materials and Methods 
Chemicals and Reagents. The following antibodies used in this study 
were purchased from the indicated vendors: Cell Signaling Technology 
 39
(Danvers, MA): β-site amyloid precursor protein cleaving enzyme 1 
(BACE1; 5606S), presenilin 1 (PS-1; 5643), β-actin (3700); BD 
Transduction Laboratories (San Jose, CA): binding immunoglobulin 
protein (BiP; 610978); Abcam (Cambridge, MA): amyloid precursor 
protein (APP; ab32136), a disintegrin and metalloproteinase domain-
containing protein 10 (ADAM10; ab1997), microtubule-associated 
protein 2 (MAP2; ab5392); Sigma Aldrich (St. Louis, MO): Actin (A2066); 
BioLegend (San Diego, CA): MAP2 (801801). The mouse monoclonal 
antibody against BACE1 (3d5) was a generous gift from Dr. Robert 
Vassar (Feinberg School of Medicine, Northwestern University, Chicago, 
IL). The antibody against Aβ-oligomers (Nab61) was kindly provided by 
Dr. Virginia Lee (The Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, PA). The following chemical reagents used 
in the study were purchased from the indicated vendors: Citifluor 
(London, UK): 4’,6-diamidino-2-phenylindole (DAPI); Invitrogen 
(Carlsbad, CA): Dulbecco’s Modified Eagle’s Medium (DMEM), 
neurobasal medium, B27 supplement; BioRad (Hercules, CA): Bradford 
protein assay dye, polyvinylidene fluoride (PVDF) membrane, prestained 
broad range molecular weight ladder; Sigma Aldrich (St. Louis, MO): 
Tween 20, Triton X-100, Fast Green FCF, protease inhibitor cocktail, 
bovine serum albumin (BSA), dimethyl sulfoxide (DMSO), cytosine β-D-
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arabinofuranoside hydrochloride (AraC); Peptides International 
(Louisville, KY): Poly-L-Lysine; Scytek Labs (Logan, UT): normal 
antibody diluent (NAD); Thermo Fisher Scientific (Waltham, MA): Hank’s 
Balanced Salt Solution (HBSS), Trypsin, GlutaMAX; Millipore (Temecula, 
CA): Luminata Classico ECL, β-secretase inhibitor (BSI) II & IV; Tocris 
Bioscience (Bristol, UK): amino-5-phosphonovaleric acid (AP5), 6-
cyano-7-nitroquinoxaline-2,3-dione (CNQX), dizocilpine (MK-801). All 
horse radish peroxidase (HRP)-conjugated secondary antibodies were 
obtained from Thermo Fisher Scientific, and all fluorescent dye-
conjugated secondary antibodies were obtained from Jackson 
ImmunoResearch Labs (West Grove, PA).  
 
Immunofluorescence of human tissue. Paraffin-embedded tissue 
sections from the hippocampus of control and HIV(+) human autopsy 
cases obtained from the National NeuroAIDS Tissue Consortium (NNTC) 
were prepared for immunofluorescent staining with minor modifications 
of previously described protocols (Lindl et al. 2007). The age, 
neurocognitive status, sex, and postmortem interval of each human 
specimen was provided by the NNTC (Table 1). Glass slides containing 
paraffin-embedded tissue sections (10 μM) were heated overnight to 
55°C, deparaffinized in histoclear and rehydrated in 100%, 95%, 90%, 
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and 70% ethanol washes. Tissue was then incubated in 3% H202 in 
methanol to inactivate endogenous peroxidase activity. Antigen 
unmasking was performed with target retrieval solution at 95°C for 1 h. 
Sections were then blocked with 10% normal goat serum and incubated 
with primary antibody overnight at 4°C. Tyramide amplification was 
used to detect BACE1 and DNA was visualized with DAPI staining. Slides 
were washed with phosphate buffered saline plus 0.1% Tween-20 (PBS-
T) and mounted in Citifluor AF1 and analyzed by laser confocal 
microscopy at 600x on a Radiance 2100 equipped with Argon, Green 
He/Ne, Red Diode, and Blue Diode lasers (BioRad). Post-acquisition 
analysis was performed using Metamorph 6.0 (Universal Imaging, 
Downingtown, PA). Total intensity for MAP2 was determined by the 
measurement of integrated pixel intensity per z-stack image, where 
integrated pixel intensity is defined as total pixel intensity per image 
times the area of pixels with positive MAP2 signal. Data were analyzed 
using GraphPad Prism statistical software (version 5.0; GraphPad, San 
Diego, CA), and data are expressed as mean ± standard error of the 
mean (SEM).  
 
Immunoblotting of human tissue. Flash-frozen whole-brain tissue 
samples from HIV (-) control (n=4), HIV (+) neurocognitively normal 
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(n=8), and HIV (+) HAND (n=6) human autopsy cases were obtained 
from the tissue banks of the NNTC. Frontal cortex was dissected from 
Brodmann areas 9 or 10. Tissue was prepared for western blotting as 
described previously (Lindl et al. 2007). Briefly, frozen brain tissue (100 
mg) was homogenized and solubilized in ice-cold tissue extraction buffer 
(50 mM Tris pH 7.5, 0.5M NaCl, 1% NP-40, 1% SDS, 2 mM EDTA, 2 mM 
EGTA, 5 mM NaF, 0.4 mM Na3VO4, 1 mM dithiothreitol (DTT) and 1:100 
protease inhibitor cocktail). Extracts were then centrifuged at 12,000 g 
at 4oC for 20 min. 30 μg protein for each sample was loaded into each 
lane of 10% Bis-Tris gels and transferred to PVDF membranes followed 
by blocking with tris buffered saline plus 0.1% Tween-20 (TBS-T) with 
5% BSA for 30 min at room temperature. Membranes were probed with 
various primary antibodies overnight at 4°C.   
 
Preparation of primary rat cortical neuron cultures. Primary rat cortical 
cultures were prepared from embryonic day 18 Sprague-Dawley rat 
embryos (Charles River Laboratories, Seattle, WA). Brains were isolated, 
and dissected cortices were incubated for 40 minutes in DMEM + 0.027% 
trypsin as described previously (Wilcox et al. 1994). Cells were then 
washed in saline, triturated, resuspended in neurobasal media 
supplemented with B27, and plated on poly-L-lysine-coated 6-well (9.4-
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cm2 growth area) or 24-well (1.9-cm2 growth area) plates (USA 
Scientific, Ocala, FL) at a concentration of 750,000 cells/ml. After 48 h, 
cells were treated with 10 µM AraC to remove dividing glial cells. 
Cultures were maintained in neurobasal media supplemented with B27 
at 37°C with 5% CO2 as described previously (Gannon et al. 2017; Akay 
et al. 2011). On 10 days in vitro (DIV), 20% fresh media was added. 
Cells were treated on DIV 14–21. 
 
Preparation of primary mouse cortical neuroglial cultures (MCCs). 
Primary mouse cortical cultures were prepared from ED 16-18 c57/BL6 
wild type or APP-/- mouse embryos (The Jackson Laboratory, Bar Harbor, 
ME). Brains were isolated, and dissected cortices were incubated for 15 
min in HBSS + .025% trypsin. Cells were then washed with saline, 
triturated, and resuspended in neurobasal media + B27 supplement + 
GlutaMAX before plating on poly-L-lysine coated 6-well (9.4 cm2 growth 
area) or 24-well (1.9cm2 growth area) plates (USA Scientific) at a 
concentration of 250,000 cells/ml. Cells were maintained at 37°C in 5% 
CO2 as described previously (Gannon et al. 2017; Akay et al. 2011) and 
were treated on DIV 14.  
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Drug treatments. Cells were treated for the time and dose specified for 
each experiment with either NMDA dissolved in H2O, MK-801 dissolved 
in DMSO, AP-5 dissolved in H2O, or CNQX dissolved in DMSO; or β-
secretase inhibitor (BSI) II or IV dissolved in DMSO. Pretreatments with 
MK-801, AP-5, and CNQX were 1 h prior to treatment with HIV/MDM 
supernatant for 16 or 24 h. Pretreatments with BSI were 1 h prior to 24 
h treatment with HIV/MDM supernatant or NMDA.  
 
HIV/MDM supernatants. Monocytes were isolated from healthy human 
donors and differentiated into macrophages before infection with HIV-1 
as previously described (Cross et al. 2011). Briefly, macrophages were 
exposed to HIV-1 T-cell propagated virus (89.6) for 24 h before virus 
was removed and cells were rinsed thoroughly with DMEM. 
Supernatants were then collected every 3 days, and macrophage 
infection was confirmed by HIV reverse transcriptase (RT) assay. DIV 
14-21 rat neuronal cultures were treated with a 1:20 – 1:80 dilution of 
HIV/MDM supernatant; results presented are those in which dilutions 
led to ~50% MAP2 loss after 24 h.   
 
Immunofluorescence of primary neuron cultures. Following treatment, 
cells were rinsed with PBS and fixed with 4% paraformaldehyde for 20 
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min. Cells were then rinsed twice in PBS and three times in PBS-T, 
followed by a 30-min incubation with a blocking/permeabilization 
solution containing 0.2% BSA + 0.1% Triton-X in PBS. Cells were rinsed 
three times in PBS-T and incubated with MAP2 primary antibody diluted 
at 1:4000 in NAD for 2 h at room temperature. Following three washes 
in PBS-T, cells were then incubated with a FITC-conjugated goat anti-
mouse secondary antibody diluted at 1:500 in NAD for 30 min at room 
temperature. Cells were then imaged using a Keyence BZ-X-700 digital 
fluorescent microscope (Keyence Corporation, Itasca, IL) affixed with 
UV, FITC, Cy3, and Cy5 filters. Images captured at ×20 magnification 
were analyzed with the BZ-X Keyence software to quantify the number 
of neurons. Specifically, the number of neurons, identified as cells 
expressing MAP2, was averaged across a total of 25 fields/well, with 2–
4 wells/treatment condition for each biological replicate. Data were 
analyzed using GraphPad Prism statistical software version 7.0, and data 
are expressed as mean fold change from untreated (UT) ± SEM. 
 
Immunoblotting of cultured samples. Following treatment, cells were 
rinsed twice with PBS and lysed with whole cell lysis buffer (50 mM Tris 
pH 7.5, 120 mM NaCl, 0.5% NP-40, 0.4 mM NaF, 0.4 mM Na3VO4, and 
1:100 protease inhibitor cocktail). Protein supernatants were collected 
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with centrifugation at 20,000 g for 10 min at 4°C. Protein concentrations 
were determined using the Bradford method, and 3-5 µg total protein 
per condition was loaded into each lane of precast 10% Bis-Tris NuPAGE 
Novex gels (Thermo Fisher Scientific). Proteins were then transferred to 
PVDF membranes, which were blocked with 5% BSA in TBS-T for 1 h at 
room temperature and incubated overnight with primary antibodies at 
4°C. Following three washes in TBS-T, membranes were incubated with 
HRP-conjugated secondary antibody (1:5000 in 5% BSA + TBS-T) for 
30 min at room temperature. Bands were visualized by 
chemiluminescence with Luminata Classico ECL, and images were 
captured by film development or ChemiDoc Touch imaging system 
(BioRad). Equal loading and even transfer of samples were confirmed 
using fast green staining of the membranes. Densitometric analysis of 
band intensities was conducted using ImageJ software (v1.44, NIH), and 
all bands were normalized to fast green stain. Data were analyzed using 
GraphPad Prism statistical software version 7.0, and data are expressed 
as mean fold change from UT ± SEM. 
 
Rat Aβ ELISAs. Media was collected from NMDA-treated primary rat 
neurons at several time points. Samples were centrifuged at 4°C 20,000 
rcf for 10 min, and undiluted supernatants were assayed with a rat Aβ42- 
 47
or Aβ40-specific sandwich ELISA (Wako Chemicals, Richmond, VA) 
according to manufacturer’s protocols. Luminescence was quantified 
using a 96-well plate reader measuring at 450nm. Raw pmol/L 
concentrations were normalized to MAP2(+) cell counts for each 
treatment group. Data were analyzed using GraphPad Prism statistical 
software version 7.0, and data are expressed as mean fold change from 
UT ± SEM. 
 
Results 
Aβ oligomers are elevated HIV(+) hippocampus. Previous studies 
have shown accumulation of neurodegenerative proteins such as APP 
and/or its cleavage products in the brains of HAND patients. To 
investigate the mechanisms underlying age-related pathologies that are 
increasingly observed in HAND, we first assessed levels of Aβ oligomers 
(Aβ oligo), the Aβ species suggested to be responsible for CNS 
neurotoxicity in AD, in the hippocampus of HIV(+) patients and age-
matched HIV(-) controls (see Table 1 for a summary of cases). We 
observed elevated levels of intraneuronal Aβ oligomers in HIV(+) 
patients (Fig. 1A, Table 1). Importantly, however, we found no evidence 
of senile or diffuse Aβ plaque deposition in the hippocampus using the 
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BC05 antibody, an Aβ42-specific antibody generated by Dr. Virginia Lee 
(not shown).  
 
BACE1 is increased in both hippocampus and frontal cortex of 
HIV(+) individuals. As oligomeric Aβ is derived from cleavage of APP 
by BACE1, we determined whether BACE1 expression was altered in the 
same cohort of samples. When we stained for BACE1 in distinct regions 
of the hippocampus, we observed significantly elevated BACE1 
immunoreactivity in HIV(+) patients compared to HIV(-) controls in CA1 
and CA3, consistent with our finding of elevated Aβ oligomers, despite 
decreased microtubule-associated protein 2 (MAP2) expression (Fig. 
2A). However, no significant changes in BACE1 were observed in the 
dentate gyrus. To confirm our immunostaining findings, we assessed 
protein levels of BACE1 in whole brain lysates from the mid-frontal 
cortex of HIV(-) and HIV(+) individuals by immunoblotting. As shown in 
Fig. 2B, BACE1 was elevated in HIV(+) individuals compared to 
uninfected controls. We also replicated this result in a second 
independent cohort of HIV(-) and HIV(+) individuals, confirming 
increased BACE1 in frontal cortex with HIV (Fig. 2C, D).    
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BACE1 is increased in primary neurons treated with 
supernatants from HIV-infected human macrophages 
(HIV/MDMs). Based on our human data demonstrating a correlation 
between HIV seropositive status and elevated BACE1 levels, we used an 
in vitro model to ask whether a causal relationship exists between HIV 
and BACE1. In this model, which has been described in detail previously 
(O’Donnell et al. 2006; Cross et al. 2011), macrophages derived from 
monocytes of healthy human donors are infected with HIV-1. 
Supernatants from infected macrophages (HIV/MDM) or uninfected 
macrophages (Mock) are then used to treat primary rat cortical neurons. 
As previously shown, HIV/MDM supernatant treatment caused loss of 
MAP2(+) neurons after 24 h (Fig. 3A). To test whether HIV/MDM 
supernatants induced BACE1 in neurons, we treated neuronal cultures 
with HIV/MDM supernatants for 16 or 24 h. By 16 h, levels of BACE1 
protein were increased in HIV/MDM- but not Mock-treated neurons (Fig. 
3B, C). We then tested whether effects on BACE1 were consistent across 
multiple supernatants. We collected supernatants generated from 3 
individual healthy macrophage donors and treated neurons with Mock 
or HIV/MDM supernatants for 16 h. Levels of BACE1 protein were 
increased by treatment with all 3 supernatants tested (Fig. 3D, E).   
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BACE1 increase by HIV/MDM supernatants is dependent on 
NMDA receptor (NMDAR) signaling. Increased glutamate and 
activation of NMDAR glutamate receptors are critical components of 
neurotoxicity in HAND and AD (Kaul et al. 2001; Kocahan and Doğan 
2017) as well as in our model (O’Donnell et al. 2006). Therefore, we 
asked whether NMDARs are required for BACE1 induction. To test this, 
we pretreated primary rat neurons with either NMDAR inhibitor MK801 
or AP-5 or glutamate receptor AMPAR inhibitor CNQX 1 h prior to 16 or 
24 h treatment with HIV/MDM or Mock supernatants. As observed 
previously, neurotoxicity of HIV/MDM supernatant treatment was 
blocked by pretreatment with MK801 or AP-5, while CNQX had no effect 
after 24 h (Fig. 4A). Correspondingly, induction of BACE1 by HIV/MDM 
supernatant treatment was blocked by pretreatment with MK801 or AP-
5 but not CNQX after 16 h (Fig. 4B). These results are quantified in Figs 
4C, D. Having demonstrated the necessity for NMDAR signaling in 
BACE1 upregulation, we next asked whether NMDAR activation was 
sufficient for upregulation of BACE1. Indeed, we observed a dose-
dependent increase in BACE1 protein levels in rat primary neurons 
following 16 h treatment with NMDA alone (Fig. 4E, F).  
 
 51
NMDAR activation shifts APP processing toward the 
amyloidogenic pathway. In neurons, full length APP can be cleaved 
by either ADAM10 or BACE1, and in either case is subsequently cleaved 
by PS-1. Cleavage by ADAM10/PS-1 generates the non-amyloidogenic 
fragment P3, while BACE1/PS-1 cleavage generates Aβ monomers that 
oligomerize to form disease-associated peptides, fibrils, and plaques. 
Because we found that NMDAR signaling was both necessary and 
sufficient for BACE1 induction and neurotoxicity induced by HIV/MDM 
supernatants, in the next series of experiments we treated primary rat 
neurons directly with NMDA for 10 min, 2, 8, 16, 24, or 48 h to further 
assess changes to APP processing and secretase expression. Because 
NMDA is a synthetic compound, we also treated neurons with the 
endogenous NMDA ligand glutamate to ensure physiological relevance 
of our results. Treatment with either NMDA or glutamate for 16 h 
increased both BACE1 and PS-1 protein levels while dramatically 
decreasing ADAM10 protein levels (Fig. 5A-D). Corresponding neuronal 
cultures were fixed 10 min, 2, 8, 16, 24, or 48 h following NMDA 
treatment. Consistent with changes in protein expression playing a role 
in NMDA-induced neurotoxicity, significant loss of MAP2(+) cells did not 
occur until 24 h following treatment with NMDA (Fig. 5E). Next, we 
asked whether changes in secretase expression patterns were 
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accompanied by changes in the production of BACE1 cleavage product 
Aβ42. To test this, we collected supernatants from primary rat neurons 
treated with NMDA for 16 or 24 h and measured the concentration of 
secreted monomers of Aβ42 with a high sensitivity ELISA. After 24 h, 
Aβ42 concentration normalized to MAP2+ cells was increased in NMDA-
treated neuron supernatants (Fig. 5F).  
 
Neurotoxicity induced by either NMDA or HIV/MDM 
supernatants is partially dependent on BACE1 activity. Because 
NMDA treatment caused both BACE1 increases and neurotoxicity, we 
asked whether BACE1 activity plays a role in the mechanism of neuronal 
death induced by NMDA. Rat primary neurons were pretreated with a 
pharmacological BACE1 inhibitor (BSI) for 1 h prior to 24 h treatment 
with NMDA, and BSI pretreatment significantly decreased NMDA-
induced neurotoxicity (Fig. 6A, B). To further confirm the role of BACE1 
in neurotoxicity of our in vitro HIV model, we also pretreated rat primary 
neurons with BSI for 1 h prior to 24 h treatment with HIV/MDM or Mock 
supernatants. Again, neurotoxicity was blocked by BSI treatment (Fig. 
6C, D).  
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BACE1-mediated NMDA-induced neurotoxicity is dependent on 
the expression of APP.  BACE1 cleaves several protein targets in 
addition to APP, including sodium and potassium channels, cell adhesion 
related proteins, and others (Kim et al. 2007; Munro et al. 2016). Thus, 
we asked whether the critical function of BACE1 responsible for its role 
in NMDA-induced neurotoxicity was dependent on the presence of APP. 
To test this, neuroglia were isolated from either wild type (WT) or APP 
knock-out (APP-/-) mouse cortex at ED 16-18. Neuroglial cultures 
isolated from APP-/- mice were viable and had undetectable levels of APP 
(Fig. 7A). Consistent with our observations in rat neuronal cultures, 
NMDA induced BACE1 in both WT and APP-/- mouse neuroglia, indicating 
that cells were similarly responsive to NMDA at the level of changes in 
BACE1 expression (Fig. 7B). At the level of neurotoxicity, however, APP-
/- cultures showed a striking resistance to NMDA-induced insult as 
compared to WT cultures, with both higher NMDA concentrations and 
longer treatments needed to cause the same degree of MAP2 loss (Fig. 
7C, D). Specifically, while 5 µM NMDA led to approximately 50% MAP2+ 
cell loss following 24 h treatment in WT cultures, 10 µM NMDA was 
required to induce the same level of toxicity in APP-/- cells and 5 µM 
NMDA treatment had no effect (Fig. 7E). To determine whether APP was 
specifically required for the role of BACE1 in NMDA-induced toxicity, we 
 54
then asked whether the remaining portion of NMDA-induced 
neurotoxicity in APP-/- cells was BACE1-dependent. To test this, we first 
confirmed BACE1 dependence of NMDA-induced neurotoxicity in WT 
mouse cultures by pretreating cells with BSI for 1 h prior to 24 h 
treatment with 5 µM NMDA. Similarly to our observations in primary rat 
neurons, BACE1 inhibition significantly decreased neurotoxicity (Fig. 7F, 
H). We then repeated this experiment in APP-/- cells, with the exception 
that 10 µM NMDA was used in order to induce a similar level of toxicity 
(~50% MAP2+ cell loss) as 5 µM NMDA treatment in the WT (Fig. 7E). 
In APP-/- cells, BACE1 inhibition had no effect on NMDA-induced 
neurotoxicity after 24 h (Fig. 7G, I).  
 
Discussion 
 In the present study, we show that both BACE1 and Aβ oligomers 
are increased in brains of ART-treated HIV+ patients, and also 
demonstrate a mechanistic role for both BACE1 and APP in HIV-
associated in vitro neurotoxicity (overview presented in Fig. 8). 
Moreover, by clearly showing a necessity and sufficiency of NMDAR 
activation in engaging this mechanism, we implicate a role for BACE1 in 
classic excitotoxicity pathways relevant not only to HAND but to 
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neurodegenerative diseases more broadly (Lipton and Rosenberg 1994; 
Carvajal et al. 2016; Kocahan and Doğan 2017). 
 These data add to a growing body of evidence that there are 
overlapping neuropathological mechanisms in AD and HAND. Aβ 
oligomers are thought to be the toxic species promoting 
neuropathogenesis in AD (Kayed and Lasagna-Reeves 2013), and our 
data indicate that they may play a similar role in HAND. BACE1 is 
increased in post mortem brains of AD patients (Yang et al. 2003; 
Johnston et al. 2005), and in animal models of AD BACE1 inhibitors 
reverse neuronal loss and cognitive deficits (Ohno et al. 2004; Singer et 
al. 2005; Chang et al. 2011). To our knowledge, our study provides the 
first evidence that BACE1 is similarly altered in HIV+ patient brains, and 
that exposure to cultured media from HIV-infected MDMs can increase 
BACE1 levels in neurons. Strikingly, we and others have also shown that 
BACE1 is increased by antiretroviral drugs of at least two classes (Brown 
et al. 2014; Gannon et al. 2017), implying that ART-treated HIV+ 
patients may have additive increases in BACE1 due to influence of both 
the viral infection and the therapeutic intervention. In addition, we 
provided evidence here for a mechanistic role of BACE1 in HIV-
associated neurotoxicity in vitro. Future studies should thus investigate 
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whether BACE1 inhibitors reverse neuronal damage and cognitive 
deficits in rodent and non-human primate models of HAND.  
 Interestingly, we found that the HIV-associated increase in BACE1 
was mirrored by an increase in the APP γ-secretase PS-1 (Selkoe and 
Wolfe 2000) and a corresponding decrease in the APP α-secretase 
ADAM10 (Lammich et al. 1999). This is consistent with a previous study 
showing that NMDAR activation increased sAPPα concentration in 
neurons and conditioned media, although the authors did not investigate 
direct influence on ADAM10 protein levels (Lesné et al. 2005). Our 
observation highlights another potential similarity with 
neuropathogenesis in AD, given that ADAM10 is decreased in both post 
mortem brain and CSF of AD patients (Colciaghi et al. 2002; Bernstein 
et al. 2003; Olsson et al. 2003; Fellgiebel et al. 2009). Changes in 
ADAM10 are likely to play an important role in disease given that 
ADAM10 cleavage product sAPPα affords neuroprotection in a variety of 
contexts (Habib et al. 2017), and moreover a decrease in ADAM10 likely 
exacerbates the shift towards amyloidogenic APP cleavage due to 
increased BACE1 and PS-1.   
 Although BACE1 is well known for its role in APP cleavage, it has 
other cleavage targets including proteins involved in development, 
synaptic function, and cell-cell adhesion (Munro et al. 2016). Hence, it 
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is of critical note that in our study we determined that the mechanistic 
role of BACE1 in NMDA-induced neurotoxicity was dependent on the 
presence of APP, indicating that APP cleavage was indeed the relevant 
BACE1 function responsible for toxicity in our model. Consistent with 
this, genetic loss of APP alone also conferred resistance of neurons to 
NMDA-induced toxicity. Within the context of abnormal APP processing 
observed in brains of HIV patients here and in other studies (Green et 
al. 2005; Ortega and Ances 2014), these results indicate a potential 
pathogenic role for altered APP processing in HAND independent of 
plaque formation.  
 In apparent contradiction, however, previous studies have 
demonstrated both decreased cell viability and increased sensitivity to 
excitotoxic insult in cultured neurons lacking APP (Perez et al. 1997; 
Han et al. 2005). Others have reported no differences in susceptibility 
(Harper et al. 1998; White et al. 1998), and another study found similar 
results to ours, albeit with copper-induced neurotoxicity rather than 
direct excitotoxic insult (White et al. 1999). This discrepancy may be 
due to critical differences in the downstream effects of NMDA receptor 
activation depending on the dose and time course in question. Indeed, 
NMDA exerts opposing effects on extracellular Aβ accumulation in vivo 
depending on the dose, with lower doses increasing amyloidogenic APP 
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processing while higher doses cause a decrease (Verges et al. 2011). 
While Han and colleagues used a 300 µM dose of NMDA for 15 minutes, 
we used doses within the 5-20 µM range for longer exposures, 
attempting to mimic a more chronic disease process. Depending on the 
precise neuronal microenvironment and pathological stage, both 
mechanisms are likely to play a role given that the acute protective 
effects of sAPPα must compete against the more chronic detrimental 
effects of the amyloidogenic pathway (Hefter and Draguhn 2017). 
 Also consistent with our observation that loss of APP confers 
resistance to NMDA-induced neurotoxicity, one series of studies has 
demonstrated a role for APP in trafficking NMDARs to the cell surface 
and increasing postsynaptic excitatory currents (Cousins et al. 2009; 
Hoe et al. 2009; Innocent et al. 2012; Cousins et al. 2015). This may 
be a contributing factor to our results as well, particularly given that 
NR2B subunit localization is selectively affected by APP (Hoe et al. 2009) 
and in large part NR2B subunits mediate the neurotoxicity in our in vitro 
HIV model (O’Donnell et al. 2006). Important to note, however, is that 
although loss of APP shifted the toxicity dose curve of NMDA, the effect 
of NMDA on BACE1 expression was not changed. This indicates that 
toxicity resistance was not entirely due to changes in surface 
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expression, and may instead have resulted from decreased BACE1-
dependent toxic mechanisms.    
 Classical pathways of excitotoxic injury are well characterized, but 
there are several ways that a role for BACE1 may fit within these 
pathways or within a parallel apoptotic or necrotic mechanism. For 
instance, Lesné et al. 2005 found that changes in APP cleavage product 
concentrations induced by NMDA were prevented by either a calcium 
chelator or inhibition of calmodulin/calmodulin kinase. Given our 
observation of increased BACE1 expression following NMDA treatment, 
one possibility is that BACE1 levels are directly affected by either 
calcium or calcium-dependent enzymes. BACE1 is also increased in vitro 
by calpain (Dong et al. 2005; Liang et al. 2010), another critical factor 
in excitotoxic injury. Possible parallel mechanisms of BACE1 mediated 
toxicity due to NMDAR activation include oxidative stress-dependent 
pathways (Tong et al. 2004) and the unfolded protein response 
(O’Connor et al. 2008), which mediates BACE1 upregulation in response 
to HIV protease inhibitors (Gannon et al. 2017). Because several 
mechanisms can potentially increase BACE1 activity and/or upregulate 
its expression, the particular pathway engaged likely depends on 
multiple factors and the possibilities are not mutually exclusive.   
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 Aside from identifying a specific role for BACE1, our study adds to 
a body of literature implicating critical roles for glutamate and NMDA 
signaling in HIV neuropathogenesis. Indeed, NMDARs are 
downregulated in brains of HIV encephalitis patients (Masliah et al. 
2004), and HIV dementia patients have increased CSF glutamate levels 
that are correlated with the degree of neurocognitive impairment 
(Ferrarese et al. 1997; Ferrarese et al. 2001). In the recently developed 
EcoHIV mouse model, HIV-stimulated release of cytokines from 
microglia impaired astrocytic reuptake of glutamate, increasing 
glutamate in the extracellular space and causing NMDA-dependent 
excitotoxicity (Moidunny et al. 2016). In addition to glutamate, viral 
proteins gp120 and tat can also directly activate NMDARs (Fontana et 
al. 1997; Shin et al. 2012; Zhou et al. 2016), and NMDA antagonists 
are neuroprotective in gp120 and tat rodent models of HIV (Mucke et 
al. 1995; Anderson et al. 2004). This indicates that both increased 
glutamate and free viral particles may act in parallel to disrupt NMDA 
signaling in HIV-infected individuals.  
 In summary, we have provided further evidence for the 
involvement of BACE1 and altered APP cleavage in HAND, with a 
potential role for Aβ oligomers in particular. Few studies in the era of 
combined ART have provided clear neuropathological differences 
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between virally suppressed HIV+ individuals and HIV- controls (Gelman 
2015), further highlighting the significance of this work and the potential 
importance of BACE1 as a biomarker or therapeutic target. Moreover, 
by identifying both NMDAR signaling and altered APP processing as 
critical factors mediating the role of BACE1 in HIV-associated 
neurotoxicity, we provide support for the potential efficacy of several 
avenues for therapeutic intervention in HAND in addition to direct 
pharmacological targeting of BACE1.    
Table 2-1. Summary of human cases used for immunofluorescence staining in 
figure 2-1 
ANNTC, National NeuroAIDS Tissue Consortium identification. BHIV infection status. 
CNeurocognitive diagnosis. DPostmortem interval (hours). EPatients medicated on 
antiretroviral drugs for greater than 12 months. FExtent of hippocampal Aβ oligomer 
burden as assessed by Nab61 staining. GNot available. F = female, M = male.  
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Figure 2-1. Aβ oligomers are elevated in the brains of HIV(+) cases  
Paraffin-embedded tissue sections from hippocampus of HIV(-) and HIV(+) 
individuals were prepared for immunofluorescent analysis and visualized by laser 
confocal microscopy. Representative images are shown from hippocampal sections 
triple-labeled for Aβ oligomers (red), MAP2 (green), and nuclei (blue). Red and green 
colocalization appears yellow.  
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Figure 2-2. BACE1 protein is increased in hippocampus and frontal cortex of 
HIV+ individuals  
A) CA1, CA3, and dentate gyrus hippocampal sections were double-labeled for BACE1 
(green) and MAP2 (red). Representative images and quantification are shown (two 
sample t-test, HIV(-) n=3, HIV(+) n=10, *p<0.05, ns: not significant). B) Lysates from 
the mid-frontal cortex of HIV(-) controls (n=5) and HIV(+) cases (n=13) were 
prepared for immunoblot and probed for BACE1. Representative blots are shown. FG 
= fast green loading control. C) In an additional cohort, lysates from mid-frontal 
cortex of HIV(-) controls (n=20) and HIV(+) cases (n=40) were prepared for 
immunoblot and probed for BACE1 and actin as a loading control. Representative 
blots are shown. D) Results from second cohort are quantified across all blots 
(ANOVA followed by Newman-Keuls, *p<0.05). Red lines indicate mean ± SEM.    
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Figure 2-3. BACE1 is increased in primary neurons following treatment with 
HIV-infected monocyte-derived macrophage supernatants (HIV/MDMs)  
A) Primary rat neurons were treated with Mock or HIV/MDM supernatants at a 
dilution causing 50% MAP2 loss after 24 h. Representative images of MAP2 (green) 
are shown. B) Whole cell lysates were collected following 16 or 24 h treatment with 
Mock or HIV/MDM supernatants, and lysates were probed for BACE1. Representative 
blots are shown. C) Densitometric analysis of western blots revealed a significant 
increase in BACE1/β-actin following 16 h HIV/MDM treatment (paired t-test, n=5, 
*p<0.05). D) HIV/MDM supernatants were generated from 3 separate healthy 
monocyte donors and were used to treat primary neurons for 16 h. Representative 
blots are shown. E) Increases in BACE1 by 16 h HIV/MDM treatment were consistent 
across HIV/MDM and Mock supernatants generated from multiple macrophage 
donors (paired t-test, n=3, *p<0.05). Dotted lines represent UT cultures. 
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Figure 2-4. NMDAR signaling is necessary and sufficient for BACE1 upregulation 
by HIV/MDM supernatants 
A) Primary rat neurons were pretreated for 1 h with 10 µM NMDAR antogonist 
MK801, 100 µM NMDAR antagonist AP-5, or 30 µM AMPAR antagonist CNQX prior to 
24 h treatment with Mock or HIV/MDM supernatants. Representative images are 
double labeled for MAP2 (green) and nuclei (blue). B) Identical pretreatments were 
performed for a separate of cultures harvested following 16 h treatment with Mock 
or HIV/MDM supernatants. Representative blots are shown. C) Number of MAP2+ 
cells was quantified across 24 h treatment groups (repeated measures two-way 
ANOVA followed by Dunnett’s test, n=3, ****p<0.0001). D) Densitometric analysis of 
BACE1/FG was used to quantify levels of BACE1 protein across 16 h treatment groups 
(repeated measures two-way ANOVA followed by Dunnett’s test, n=3, *p<0.05, 
***p<0.001, ****p<0.0001). E)  Cultures were treated with 5, 10, or 20 µM NMDA for 
16 h and assessed for BACE1 protein levels. Representative blots are shown. F) 
Densitometric analysis of BACE1/FG was used to quantify levels of BACE1 protein 
(repeated measures one-way ANOVA followed by Dunnett’s test, n=4-5, *p<0.05). 
Dotted lines represent UT cultures. FG = fast green loading control.  
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Figure 2-5. NMDAR signaling shifts APP cleavage toward the amyloidogenic 
pathway  
A) Primary rat neurons were treated with 10µM NMDA or 10µM glutamate for 10 
min, 2, 8, 16, 24, or 48 h. Whole cell lysates were collected and assessed for BACE1, 
PS-1, and ADAM10 expression; representative blots are shown. B-D) Densitometric 
analysis of each secretase compared to FG was used to quantify protein levels across 
time points (repeated measures two-way ANOVA followed by Dunnett’s test, n=3-4, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). FG = fast green loading control. E) 
Number of MAP2+ cells was quantified following 10 µM NMDA treatment (repeated 
measures two-way ANOVA followed by Sidak’s test, n=4, *p<0.05, **p<0.01.) F) 
Conditioned media from primary rat neurons was collected following 24 h treatment 
with 10 µM NMDA, and sample concentrations of Aβ42 were measured using a 
sandwich ELISA. Concentrations were normalized to the number of MAP2+ cells in 
identically treated cultures within each biological replicate (paired t-test, n=3, 
*p<.05). Dotted lines represent UT cultures.  
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Figure 2-6. Neurotoxicity induced by either NMDA or HIV/MDM supernatants is 
dependent on BACE1 activity  
A) Primary rat neurons were pretreated with DMSO vehicle or 100 nM BSI II for 1 h 
prior to 24 h treatment with 10 µM NMDA. Representative images are double labeled 
for MAP2 (green) and nuclei (blue). B) Number of MAP2+ cells was quantified across 
treatment groups (repeated measures two-way ANOVA followed by Tukey’s test, n=4, 
*p<0.05 vs treatment vehicle, #p<0.05 vs pretreatment vehicle). C) Primary rat 
neurons were pretreated with DMSO vehicle or 5 µM BSI IV for 1 h prior to 24 h 
treatment with Mock or HIV/MDM supernatants. Representative images are double 
labeled for MAP2 (green) and nuclei (blue). D) Number of MAP2+ cells was quantified 
across treatment groups (repeated measures two-way ANOVA followed by Tukey’s 
test, n=4, **p<0.01 vs Mock, #p<0.05 vs pretreatment vehicle). Dotted lines represent 
UT cultures.  
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Figure 2-7. APP is required for BACE1-dependent neurotoxicity.  
A) Primary neuroglia were isolated from WT or APP-/- mice and assessed for levels of 
APP by western blot. Representative blots are shown. B) WT or APP-/- neuroglial 
cultures were treated with 5 or 10 µM NMDA for 16 h and whole cell lysates were 
collected and assessed for BACE1. Representative blots are shown. FG = fast green 
loading control. C) WT and D) APP-/- cultures were treated with 5, 10, or 20 µM NMDA 
for 4, 16, or 24 h. Number of MAP2+ cells was quantified across treatment groups. E) 
Data from C and D 5 and 10 µM 24 h NMDA treatment groups only were replotted to 
show direct comparison between WT and APP-/- responses. F) WT and G) APP-/- 
cultures were pretreated with DMSO vehicle or BSI for 1 h prior to 24 h treatment 
with 5 µM (WT) or 10 µM (APP-/-) NMDA. Representative images are double labeled 
for MAP2 (green) and nuclei (blue). H-I) Number of MAP2+ cells was quantified 
across treatment groups (repeated measures two-way ANOVA followed by Dunnett’s 
test, n=3-4, *p<0.05, **p<0.01, ***p<0.001). Dotted lines represent UT cultures.  
  
 70
 
Figure 2-8. Hypothesis overview: BACE1 and APP mediate NMDAR-dependent 
neuronal damage associated with HIV.  
Data presented herein support the hypothesis that BACE1 mediates neuronal damage 
induced by NMDA receptor activation. Specifically, we propose that in an HIV+ 
individual, HIV-infected macrophages in the brain release increased levels of 
glutamate and/or fail to adequately regulate glutamate levels in the extracellular 
space. Increased extracellular glutamate leads to chronic activation of NMDA 
receptors on neurons, which causes increased expression of BACE1 protein. 
Increased BACE1 expression then results in increased processing of APP and higher 
concentrations of amyloid-β, which lead to neuronal damage over time.  
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CHAPTER 3: DIFFERENTIAL EFFECTS OF 
ANTIRETROVIRALS ON NEURONS IN VITRO: A ROLE 
FOR THE ENDOGENOUS ANTIOXIDANT RESPONSE 
Anna L Stern, Rebecca N Lee, Nina Panvelker, Jiean Li, Jenna 
Harowitz, Kelly L Jordan-Sciutto, and Cagla Akay-Espinoza  
 
Abstract 
 Mounting evidence suggests that antiretroviral drugs may 
contribute to the persistence of HIV-associated neurocognitive disorder 
(HAND), which impacts 30%–50% of HIV-infected patients in the post-
antiretroviral era. We previously reported that two first generation HIV 
protease inhibitors, ritonavir and saquinavir, induced oxidative stress 
and the unfolded protein response, with subsequent neuronal death in 
vitro, which was reversed by augmentation of the endogenous 
antioxidant response by monomethyl fumarate. We herein determined 
whether two newer-generation PIs, darunavir and lopinavir, were 
deleterious to neurons in vitro. Further, we expanded our assessment 
to include three integrase strand transfer inhibitors, raltegravir, 
dolutegravir, and elvitegravir. We found that only lopinavir and 
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elvitegravir were neurotoxic to primary rat neuroglial cultures as 
determined by the loss of microtubule-associated protein 2 (MAP2). 
Intriguingly, lopinavir but not elvitegravir led to oxidative stress and 
induced the endogenous antioxidant response. Furthermore, 
neurotoxicity of lopinavir was blocked by pharmacological augmentation 
of the endogenous antioxidant heme-oxygenase 1 (HO-1), expanding 
our previous finding that protease inhibitor-induced neurotoxicity was 
mediated by oxidative stress. Intriguingly, we found that neurotoxicity 
was induced only by a subset of protease inhibitors and integrase strand 
transfer inhibitors, providing evidence for class- and drug-specific 
neurotoxic effects of antiretroviral drugs. Future in vivo studies will be 
critical to confirm the neurotoxicity profiles of these drugs for 
incorporation of these findings into patient management. The 
endogenous antioxidant response is a potential access point for the 
development of adjunctive therapies to complement antiretroviral 
therapies and limit their contribution to HAND persistence.  
 
Introduction 
 Human immunodeficiency virus (HIV) affects 36.9 million people 
globally (UNAIDS 2015) and 1.1 million people in the United States 
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alone (Centers for Disease Control and Prevention 2016). Left 
untreated, HIV replicates in blood and tissues, eventually leading to 
debilitating loss of immune function defined as acquired immune 
deficiency syndrome (AIDS). AIDS patients are susceptible to 
opportunistic infections which are often lethal. However, the 
introduction of combination antiretroviral therapy in 1996 transformed 
HIV diagnosis from a death sentence into a chronic, manageable 
condition with minimal to no effect on life expectancy in the absence of 
comorbidities (Lai et al. 2006; Teeraananchai et al. 2016).  
 Despite the pronounced benefits of antiretroviral therapy, the 
incidence of neurological complications among HIV-infected individuals 
has not declined. In fact, HIV-associated neurocognitive disorder 
(HAND) remains prevalent, with estimates ranging between 15% and 
55% in HIV-infected patients (Saylor et al. 2016). Although the 
diagnosis of severe neurological dysfunction, termed HIV-associated 
dementia (HAD), is now rare, the incidence of both asymptomatic 
neurocognitive impairment (ANI) and mild neurocognitive disorder 
(MND) has increased (Sacktor et al. 2016). Additionally, while 
approximately 70% of HAND patients are asymptomatic, ANI patients 
are two to six fold more likely than neurocognitively normal patients to 
progress to symptomatic disease (Grant et al. 2014b). Moreover, with 
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the expected increase in life expectancy of HIV-infected individuals 
afforded by antiretroviral therapy, age-related changes in the central 
nervous system (CNS) may exacerbate HAND symptoms (Gelman and 
Schuenke 2004; Cohen et al. 2015; Tan et al. 2013).  
 Persistence of HAND despite viral suppression by antiretroviral 
therapy is not well understood. The cause is likely multifactorial, with 
contributions from HIV-related factors (Kaul and Lipton 2006; Chen et 
al. 2014) as well as from antiretroviral drugs (ARVs) themselves 
(Treisman and Soudry 2016; Shah et al. 2016). Several studies found 
that ARVs with higher CNS penetration effectiveness were associated 
with more frequent neurological symptoms, indicating a role for ARV 
toxicity (Marra et al. 2009; Caniglia et al. 2014; but see Carvalhal et al. 
2016; Smurzynski et al. 2011 for alternative results). Numerous studies 
also demonstrated the potential for ARVs to cause oxidative stress, 
endoplasmic reticulum (ER) stress, and mitochondrial dysfunction, with 
subsequent synaptodendritic damage and neuron loss both in vivo and 
in vitro (Akay et al. 2014; Gannon et al. 2017; Robertson et al. 2012b; 
Brown et al. 2014). As neurotoxicities associated with different ARVs 
may vary, and given the continuing development of newer and more 
effective ARVs, questions remain regarding the potential for current 
therapies to instigate long-term adverse neurological effects.   
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 ARVs can be broadly categorized into five classes according to 
their mechanism of action: entry inhibitors, nucleoside reverse 
transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase 
inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), and 
protease inhibitors (PIs). Currently, the United States Department of 
Health and Human Services (DHHS) recommends that frontline 
treatment for adult HIV-infected individuals should include either an 
INSTI or a PI in combination with two NRTIs (DHHS 2016a). We 
previously showed that two first generation PIs, ritonavir and 
saquinavir, led to oxidative stress and neurotoxicity. Herein, we 
expanded our investigation to include three INSTIs, elvitegravir (EVG), 
dolutegravir (DTG), and raltegravir (RAL), as well as two commonly 
used PIs darunavir (DRV) and lopinavir (LPV). All are currently 
recommended by the DHHS as frontline treatment options for adults and 
adolescents, except for LPV which is recommended by the DHHS and 
the WHO for all children under three years of age (DHHS 2016a; WHO 
2016a). We investigated the neurotoxicity profiles of these ARVs in vitro 
and examined the underlying mechanisms contributing to toxicity.  
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Materials and Methods 
Chemicals and Reagents. The following antibodies were purchased from 
the indicated vendors: Enzo Life Sciences (Farmingdale, NY): heme-
oxygenase 1 (HO-1, ADI-SPA-896); Abcam (Cambridge, MA): 
glutathione-S-reductase (GSR, ab16801); Cell Signaling Technology 
(Danvers, MA): phosphorylated eukaryotic initiation factor 2α (peIF2α, 
9721), total eIF2α (9722); BD Transduction Laboratories (San Jose, 
CA): binding immunoglobulin protein (BiP, 610978); BioLegend (San 
Diego, CA): microtubule-associated protein 2 (MAP2, 801801). The 
following chemical reagents were purchased from the indicated vendors: 
Citifluor (London, UK): 4’,6-diamidino-2-phenylindole (DAPI); 
Invitrogen (Carlsbad, CA): Dulbecco’s Modified Eagle’s Medium (DMEM), 
neurobasal medium, B27 supplement; BioRad (Hercules, CA): Bradford 
protein assay dye, polyvinylidene fluoride (PVDF) membrane, prestained 
broad range molecular weight ladder; Sigma Aldrich (St. Louis, MO): 
Tween 20, Triton X-100, Fast Green FCF, protease inhibitor cocktail, 
bovine serum albumin (BSA), dimethyl sulfoxide (DMSO); Peptides 
International (Louisville, KY): Poly-L-Lysine; Scytek Labs (Logan, UT): 
normal antibody diluent (NAD); Millipore (Temecula, CA): Luminata 
Classico ECL; Thermo Fisher Scientific (Waltham, MA): CellRox Green, 
tetramethylrhodamine methyl ester (TMRM); Tocris Bioscience (Bristol, 
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UK): 1-(2-Cyano-3,12,28-trioxooleana-1,9(11)-dien-28-yl)-1H-
imidazole (CDDO). All horse radish peroxidase (HRP)-conjugated 
secondary antibodies were obtained from Thermo Fisher Scientific, and 
all fluorescent dye-conjugated secondary antibodies were obtained from 
Jackson ImmunoResearch Labs (West Grove, PA). ARVs were kindly 
provided by the AIDS Research and Reference Reagent Program, 
Division of AIDS, National Institute of Allergy and Infectious Diseases, 
NIH (Bethesda, MD).  
 
Preparation of primary rat cortical neuroglial cultures. Primary rat 
cortical cultures were prepared from embryonic day 18 Sprague-Dawley 
rat embryos (Charles River Laboratories, Seattle, WA). Brains were 
isolated, and dissected cortices were incubated for 40 minutes in DMEM 
+ 0.027% trypsin as described previously (Wilcox et al. 1994). Cells 
were then washed in saline, triturated, resuspended in neurobasal 
media supplemented with B27, and plated on poly-L-lysine-coated 6-
well (9.4-cm2 growth area) or 24-well (1.9-cm2 growth area) plates 
(USA Scientific, Ocala, FL) at a concentration of 500,000 cells/ml. 
Cultures contained approximately 90% neurons and 10% 
astrocytes/glia and were maintained in neurobasal media supplemented 
with B27 at 37°C with 5% CO2 as described previously (Gannon et al. 
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2017; Akay et al. 2011). On 10 days in vitro (DIV), 20% fresh media 
was added. Cells were treated on DIV 14–16. 
 
Drug treatments. Cells were treated with individual ARVs for the times 
and doses as indicated. DTG, RAL, and EVG were prepared as 50 mM 
stock solutions in DMSO, whereas RTV, LPV, and DRV were prepared as 
25 mM stock solutions in DMSO. In specific experiments, CDDO 
(prepared as 50 mM stock solution in DMSO) was used for 1-h 
pretreatment before the indicated ARV treatments.  
 
Immunofluorescence. Following treatment, cells were rinsed with 
phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde 
for 20 min. Cells were then rinsed twice in PBS and three times in PBS 
containing 0.1% Tween 20 (PBS-T), followed by a 30-min incubation 
with a blocking/permeabilization solution containing 0.2% BSA + 0.1% 
Triton-X in PBS. Cells were rinsed three times in PBS-T and incubated 
with MAP2 primary antibody diluted at 1:4000 in NAD for 2 h at room 
temperature. Following three washes in PBS-T, cells were then 
incubated with a FITC-conjugated goat anti-mouse secondary antibody 
diluted at 1:500 in NAD for 30 min at room temperature. Cells were then 
imaged using a Keyence BZ-X-700 digital fluorescent microscope 
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(Keyence Corporation, Itasca, IL) affixed with UV, FITC, Cy3, and Cy5 
filters. Images captured at ×20 magnification were analyzed with the 
BZ-X Keyence software to quantify the number of neurons. Specifically, 
the number of neurons, identified as cells expressing MAP2, was 
averaged across a total of 25 fields/well, with 2–4 wells/treatment 
condition for each biological replicate. Data were analyzed using 
GraphPad Prism statistical software (version 7.0; GraphPad, San Diego, 
CA), and data were expressed as mean fold change from untreated (UT) 
± standard error of the mean (SEM). 
 
Immunoblotting. Following treatment, cells were rinsed twice with PBS 
and lysed with whole cell lysis buffer (50 mM Tris pH 7.5, 120 mM NaCl, 
0.5% NP-40, 0.4 mM NaF, 0.4 mM Na3VO4, and 1:100 protease 
inhibitor cocktail). Protein supernatants were collected with 
centrifugation at 20,000 g for 10 min at 4°C. Protein concentrations 
were determined using the Bradford method, and 3-5 µg total protein 
per condition was loaded into each lane of precast 10% Bis-Tris NuPAGE 
Novex gels (Thermo Fisher Scientific). Proteins were then transferred to 
PVDF membranes, which were blocked with 5% BSA in tris-buffered 
saline containing 0.1% Tween 20 (TBS-T) for 1 h at room temperature 
and incubated overnight with primary antibodies at 4°C. Following three 
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washes in TBS-T, membranes were incubated with HRP-conjugated 
secondary antibody (1:5000 in 5% BSA + TBS-T) for 30 min at room 
temperature. Bands were visualized by chemiluminescence with 
Luminata Classico ECL, and images were captured by film development 
or ChemiDoc Touch imaging system (BioRad). Equal loading and even 
transfer of samples were confirmed using fast green staining of the 
membranes. Densitometric analysis of band intensities was conducted 
using ImageJ software (v1.44, NIH), and all bands were normalized to 
fast green stain. Data were analyzed using GraphPad Prism statistical 
software, and data were expressed as mean fold change from UT ± SEM. 
 
CellRox Green live cell imaging. CellRox Green oxidative stress detection 
reagent was purchased as a stable 2.5-mM solution dissolved in DMSO. 
Aliquots were stored at −20°C protected from light and with a desiccant, 
thawed just prior to use. Directly following drug treatments, CellRox was 
added to cell media at a final concentration of 5 µM and incubated at 
37°C for 30 min according to manufacturer’s instructions. Cells were 
then visualized at 20× using Keyence BZ-X-700 digital fluorescent 
microscope by time-lapse live cell imaging. Images of each well were 
captured approximately every 6 min for 1 h following the incubation 
period. Cell media were then removed, and cells were rinsed and fixed 
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with 4% paraformaldehyde for 20 min prior to immunofluorescence 
staining, as described above. Images of cells stained with MAP2/DAPI 
were then merged with CellRox Green images using Adobe Photoshop. 
Quantification of CellRox Green fluorescence was achieved using 
Keyence BZ-X analysis software. Data were analyzed using GraphPad 
Prism statistical software, and data were expressed as mean fold change 
from UT ± SEM. 
 
Results 
Elvitegravir but not dolutegravir or raltegravir is toxic to neurons 
in vitro. Given that INSTIs are an integral part of the updated frontline 
treatment for HIV, we first determined the effects of three commonly 
prescribed INSTIs, EVG, DTG, and RAL, on MAP2 expression in primary 
neuroglial cultures. We treated cells with individual ARVs at 0.1, 1, or 
10 µM either one time for two days or every other day for four days (see 
Table 1 for comparison with in vivo concentrations of INSTIs used in this 
study). While 2- and 4-day treatments with EVG at lower concentrations 
did not lead to neuronal damage as determined by the reduction in the 
number of MAP2-positive cells, 10 µM EVG led to an average of 76% 
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MAP2 loss at 4 days (Fig. 1A, B). In contrast, neither DTG (Fig. 1A, C) 
nor RAL (Fig. 1A, D) was neurotoxic at any dose or time point tested.  
 
Lopinavir but not darunavir is toxic to neurons in vitro. PIs are 
the second most commonly prescribed ARVs. Specifically, DRV is the 
only currently recommended frontline PI for adults in the United States, 
whereas LPV is the PI of choice both in the United States and globally 
for the treatment of children under the age of three (DHHS 2016a; WHO 
2016a). Hence, we determined the effects of these drugs on MAP2 
expression in primary neuroglial cultures. We treated cells with ARVs 
individually at either 0.1, 1, or 10 µM for 2 days (see Table 1 for 
comparison with in vivo measured concentrations of PIs used in this 
study). At lower concentrations, LPV was not toxic; however, 10 µM LPV 
led to an average of 54% MAP2 loss (Fig. 2A, B). In contrast, DRV was 
not toxic at any dose after 2 days. Surprisingly, treatment with 0.1 µM 
DRV led to an increase in the number of MAP2+ cells compared with the 
vehicle control (Fig. 2A, C).  
 In clinical practice, PIs are often administered with a low “booster” 
dose of RTV to inhibit the metabolism of concomitantly prescribed ARVs 
and increase their bioavailability. These combinations are packaged into 
fixed-ratio pill forms such that RTV dose is increased by the same ratio 
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as the primary PI if the regimen is altered. Based on our previous work 
demonstrating that RTV was neurotoxic at 10 µM in vitro (Gannon et al. 
2017; Akay et al. 2014), we determined whether lower doses of RTV 
administered as part of an ARV regimen could alter the effects of other 
PIs. Cells were treated for 2 days with LPV or DRV at 0.1, 1, or 10 µM 
concentrations either alone or with corresponding RTV booster 
concentrations of 0.02, 0.2, or 2 µM, respectively. Although 2 µM RTV 
was neurotoxic after two days regardless of concomitant treatment with 
DRV, none of the combinations tested were more toxic than either ARV 
alone (Fig. 2D).  
 
Lopinavir but not elvitegravir increases reactive oxygen species 
(ROS). We previously observed that ARVs caused oxidative stress in 
the CNS in vivo (Akay et al. 2014). Therefore, we next determined 
whether LPV and EVG led to ROS accumulation in neurons. The oxidative 
stress indicator CellRox Green was added to the culture media together 
with LPV or EVG, and live cell imaging was conducted 1 h later as 
described in the Methods section. The green fluorescence in the nucleus, 
indicating the accumulation of the oxidized compound in the presence 
of ROS, was significantly increased by LPV compared to DMSO vehicle 
control. In contrast to LPV, however, EVG did not lead to an increase in 
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ROS; instead, both DMSO and EVG led to a reduction in ROS levels even 
below those measured in untreated cultures (Fig 3A, B). 
 
Lopinavir but not elvitegravir activates the endogenous 
antioxidant response. Based on our observation of oxidative stress 
induced by LPV, we sought to determine whether the endogenous 
antioxidant response was activated. To that end, we assessed the levels 
of heme-oxygenase 1 (HO-1), a canonical indicator of endogenous 
antioxidant response activation with potent antioxidant properties, in 
lysates prepared from cultures treated with 0.1, 1, or 10 µM LPV for 4, 
8, or 20 h. As shown in Fig. 4A and B, we observed that HO-1 protein 
levels were increased in cultures treated with 10 µM LPV for 20 h. In 
contrast, EVG treatment had no significant effect on HO-1 (Fig. 4E, F). 
Another common mediator of cellular toxicity is ER stress, which we 
previously identified as a correlate of neuropathological changes in HIV-
infected patients (Lindl et al. 2007; Akay et al. 2012). Thus, we 
determined whether two canonical ER stress markers, BiP and phospho-
eIF2α (peIF2α), were altered in neurons exposed to 10 µM LPV or EVG 
for 4, 8, or 20 hours. Surprisingly, we observed no changes in either BiP 
or the ratio of peIF2α/teIF2α following LPV treatment (Fig. 4A, C, D). In 
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contrast, 10 µM EVG treatment led to a transient increase in 
peIF2α/teIF2α at 4 h followed by a decrease at 20 h (Fig. 3E, H).  
 
Induction of heme-oxygenase 1 by CDDO is protective against 
lopinavir-induced neurotoxicity. HO-1 is a critical endogenous 
antioxidant component of the cell, and its pharmacological induction was 
previously demonstrated to be protective against a variety of CNS 
insults including RTV-mediated neurotoxicity (Chen 2014; Cross et al. 
2011; Akay et al. 2014). Thus, we hypothesized that augmentation of 
HO-1 might be neuroprotective against LPV-induced neuronal death. 
CDDO is a triterpenoid known to induce the expression of antioxidant 
response element genes including HO-1 via activation of the 
transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) 
(Yates et al. 2007). We determined whether CDDO could augment HO-
1 expression in LPV-treated cultures. Indeed, after 20 h of treatment, 
HO-1 was increased in cultures exposed to CDDO or LPV alone and was 
further increased by the combination of both compounds (Fig. 5A, B). 
Surprisingly, under the same conditions, neither CDDO nor LPV led to a 
change in the protein levels of glutathione reductase (GSR), another 
component of the endogenous antioxidant response targeted by Nrf2 
(Fig. 5A, C). In agreement with its ability to augment HO-1 expression, 
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CDDO pretreatment was able to completely block LPV-induced 
neurotoxicity (Fig. 5D, E), indicating both a mechanistic role for 
oxidative stress in LPV-mediated neurotoxicity as well as a 
neuroprotective role for HO-1. In contrast, consistent with our observed 
lack of ROS accumulation and HO-1 induction following EVG treatment, 
CDDO had no effect on EVG-induced neurotoxicity (Fig. 5F).  
 
Discussion 
 The introduction of ART was a life-saving advancement in 
HIV/AIDS, and our most urgent goal is to expand access to therapy 
around the world (WHO 2016b). However, given the continued 
persistence of HAND despite effective viral suppression with ARVs, a 
better understanding of potential ARV neurotoxicities is necessary as 
patients remain on ART for decades due to increased lifespan. In 
particular, the most recently introduced class of ARV, INSTIs, requires 
further investigation as their worldwide use continues to grow.  
 In the present study, we investigated the in vitro effects of five 
drugs including the INSTIs EVG, DOL, and RAL and the PIs LPV and DRV, 
all of which are recommended as part of current frontline regimens for 
HIV-infected individuals in the U.S (DHHS 2016a; DHHS 2016b). 
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Neuronal damage was induced by EVG and LPV only, and LPV but not 
EVG led to oxidative stress while EVG but not LPV led to transient ER 
stress. Furthermore, by pharmacologically inducing the endogenous 
antioxidant HO-1, we were able to reverse LPV-induced neuronal 
damage. 
 Of the three INSTIs tested, only EVG caused neuronal damage in 
primary rat cultures. This within-class difference was dramatic, with EVG 
causing a 76% loss of MAP2, whereas the same dose and time course 
of treatment with DTG or RAL had no effect. These data corroborate 
previous studies showing the lack of in vitro toxicity of RAL (Blas-Garcia 
et al. 2014). Thus, it may be warranted for clinicians to consider this 
observation when deciding between the three drugs, especially in 
younger patients who are anticipated to take ARVs for several decades. 
However, it is critical to interpret these data with caution and in the full 
context of other studies. For instance, while we found no evidence of 
neurotoxicity with DTG in our model, which was consistent with many 
comprehensive studies of patient populations (Kanters et al. 2016; 
Singh et al. 2016a), other recent evidence indicates that potential CNS 
toxicity of DTG should not be overlooked (Hoffmann et al. 2017; Kheloufi 
et al. 2015; de Boer et al. 2016). Neuropsychiatric side effects of DTG 
might be due to its relatively high CNS penetration effectiveness, with 
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CSF concentrations reaching levels equivalent to those measured in 
plasma (Letendre et al. 2014). Moreover, many ARVs as well as their 
metabolites can have severe peripheral side effects including chronic 
inflammation (Troya and Bascuñana 2016), which may indirectly cause 
neuropsychiatric symptoms.  
 Additionally, we found a difference in the neurotoxic potential of 
two PIs, DRV and LPV. Specifically, LPV caused a 54% loss of MAP2, 
whereas DRV had no effect at the same dose and time course. The 
relevance of this direct comparison is highlighted by comparable 
recommended dosing and maximum plasma concentrations of the two 
drugs in patients (see Table 1). Moreover, DRV had no effect on neurons 
even when combined with low doses of RTV, as it is currently prescribed. 
Future studies should address whether combinations of DRV and 
cobicistat, the newest approved co-formulation, remain non-neurotoxic 
(Capetti et al. 2015). These results add to a growing body of in vitro 
evidence that DRV is a particularly safe treatment option (Robertson et 
al. 2012b; Blas-Garcia et al. 2014). DRV was designed to bind tightly to 
the HIV protease and limit drug resistance (Deeks 2014; Wensing et al. 
2010); moreover, DRV demonstrated superior viral suppression, 
increased CD4+ T cell counts, and a lower incidence of gastrointestinal 
side effects in a direct comparison study with LPV (Mills et al. 2009). 
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Despite these data, LPV is prescribed more frequently than DRV in 
resource-poor areas, such as Sub-Saharan Africa where over 70% of 
HIV-infected individuals reside (Saylor et al. 2016; WHO 2016a). The 
prevalence of LPV use in resource-poor settings is primarily because LPV 
is available as a generic, heat stable fixed-dose combination drug 
approved for once-daily dosing (WHO 2016a). Our study along with 
those mentioned above highlight the rationale for urgent development 
of a similar formulation of DRV available at lower cost.   
 Another relevant consideration is that LPV is recommended by the 
DHHS (2016b) and WHO (2016a) as the frontline treatment for 
newborns and children up to three years of age. In addition to the 
evidence of blood brain barrier disruption caused by HIV in general 
(Singh et al. 2016b; Nakagawa et al. 2012; Singh et al. 2014), data 
suggest that the blood brain barrier in newborns is not yet fully 
developed (Baburamani et al. 2012; Watson et al. 2006; but see 
Saunders et al. 2012 for an alternative view), which raises the possibility 
that infant brains might be exposed to higher concentrations of ARVs 
than adults. This consideration highlights the need for future studies on 
LPV and its effects on neurons in vivo, particularly in models of pediatric 
infection.    
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 In addition to characterizing the effects of LPV and EVG on 
neuronal damage indicated by MAP2 expression, we investigated several 
mechanisms that might be involved. We expected to observe ER stress, 
given previous reports by us and others showing the potential for a 
subset of ARVs to activate the ER stress response pathway in vivo and 
in vitro (Gannon et al. 2017; De Gassart et al. 2016; Weiß et al. 2016; 
Borsa et al. 2015). Interestingly, LPV did not upregulate ER stress 
markers BiP or peIF2α, indicating that the mechanism driving 
neurotoxicity might be distinct from that of other PIs (Gannon et al. 
2017). However, a lack of effect on BiP and peIF2α does not rule out the 
possibility that LPV induces ER stress. These indicators only represent 
two arms of the unfolded protein response (UPR), a multipartite 
protective cellular mechanism that is activated following ER stress, and 
other elements of the UPR may be preferentially induced in response to 
LPV. In contrast to LPV, EVG treatment transiently increased the ratio 
of peIF2α/teIF2α, indicating potential ER stress and activation of the 
UPR. This increase was no longer observed after 8 h treatment, which 
may reflect the ability of neurons to recover. This recovery is consistent 
with the observation that a single EVG treatment had no effect on MAP2 
after 2 days.     
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 In contrast to our findings related to ER stress, LPV but not EVG 
led to oxidative stress as evidenced by both increased ROS production 
and activation of the endogenous antioxidant response. These data are 
consistent with observations of ARV-associated mitochondrial 
dysfunction (Noguera-Julian et al. 2015) as well as our previous data 
linking ARVs to oxidative stress (Akay et al. 2014). Specifically, we 
found that two first-generation PIs, RTV and saquinavir, led to ROS 
accumulation in cultured neurons and that the neurotoxicity induced by 
these ARVs was blocked by augmenting the endogenous antioxidant 
response to reduce oxidative stress. In agreement with these 
observations, we herein again show a mechanistic role for oxidative 
stress in ARV-induced neuronal damage, as LPV-induced damage was 
reversed by pharmacological induction of the endogenous antioxidant 
HO-1. Further demonstrating the distinct mechanisms of toxicity across 
different ARVs, neither oxidative stress, HO-1 induction, nor protective 
potential of CDDO was observed with EVG treatment. A limitation of this 
result, however, is that because EVG induced toxicity on a different time 
scale than LPV, the possibility remains for oxidative stress and HO-1 
induction to manifest at later time points following EVG treatment. 
Regardless, differences in the neurotoxic potential and underlying 
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neurotoxic mechanisms across ARV classes as well as within each class 
are evident based on our findings.  
 One important caution in the interpretation of our data is that 
these studies were done in vitro, and cultured neurons may not respond 
to ARVs in a similar manner as neurons in vivo, even within the same 
species. Moreover, there may be species differences, which indicates a 
need for further studies on these drugs in additional rodent strains, non-
human primates, and humans. Relatedly, these studies did not identify 
the role of neuron-glia interaction in both the toxic and protective effects 
observed. Because the experiments were performed in neuroglial 
cultures, potential contributions of astrocytes and microglia should not 
be overlooked. Another legitimate concern about the relevance of our 
findings is whether the doses at which neurotoxic effects were observed 
were comparable to those expected in patients. Doses tested in the 
current study were designed to cover a wide range of concentrations, 
and the concentrations which caused neuronal damage in our in vitro 
system were higher than those observed in patient CSF samples (Table 
1). Hence, one important outcome of our study was that acute 
administrations of the five ARVs tested were not neurotoxic in vitro at 
low doses comparable to their reported concentrations in the CSF. 
However, although low doses had no effect on cell number quantified by 
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MAP2+ cell counts, the possibility of synaptic damage remains, 
consistent with our previous studies (Akay et al. 2014). Additionally, a 
critical feature of our model is its attempt to assess the chronic effects 
of ART over decades utilizing an acute model, which necessitates higher 
drug concentrations than may be observed in the CSF of patients at any 
given time. Moreover, CSF drug concentrations may not accurately 
reflect ARV concentrations in the brain parenchyma (Anthonypillai et al. 
2004). Finally, as current attempts are focused on improving the CNS 
penetration effectiveness of ARVs to increase viral suppression in the 
brain (Bertrand et al. 2016), an understanding of the neurotoxic 
potential of even relatively high drug concentrations remains important.  
 In summary, the significance of the present study is two-fold. First, 
we demonstrated that certain ARVs may have significant neurotoxic 
potential, which we hope will both aid clinicians in their decisions and 
influence momentum for ARVs with the highest safety indications to be 
made more accessible worldwide. Second, we showed that ARVs caused 
neurotoxicity through distinct cellular pathways even within a single 
drug class. As adjunctive therapies are developed in attempts to treat 
the symptoms of HAND, it may be prudent to individualize therapies and 
include strategies to protect patients based on their specific ARV 
regimens.   
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Table 3-1. Reported patient plasma and cerebrospinal fluid concentrations of 
the antiretroviral drugs evaluated  
Concentration range is provided in ng/ml and the maximum measured concentration 
is provided in µM to allow for direct comparison with doses tested in the current 
study. 
 
Drug Plasma 
concentration 
(ng/ml) 
Maximum 
plasma 
concentration 
(µM) 
CSF 
concentration 
(ng/ml) 
Maximum 
CSF 
concentration 
(µM) 
Elvitegravir1 450–1700 3.8 2.4-11.7 0.03 
Dolutegravir2  220–3340 8.0 12.6-16.2 0.04 
Raltegravir3 1140-1502 3.4 6.0-94.2 0.21 
Lopinavir4 154–16700 26.6 1.93–78.3 0.12 
Darunavir5 1800–12900 23.6 15.9–212 0.39 
  
                                    
CSF, cerebrospinal fluid 
1 (Ramanathan et al. 2011; Podany et al. 2017) 
2 (Cottrell et al. 2013) 
3 (Yilmaz et al. 2009a) 
4 (Tiraboschi et al. 2015) 
5 (Yilmaz et al. 2009b) 
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Figure 3-1. EVG but not DTG or RAL is toxic to primary rat cortical neuroglial 
cultures  
A) Cultures were treated with DMSO vehicle or 0.1 µM, 1 µM, or 10 µM EVG, DTG, or 
RAL for either 2 days or every other day for 4 days. Representative images of 
neuroglial cultures immunostained for MAP2 (green) and DAPI (blue) after treatment 
with 10 µM of indicated compounds for 4 days are shown at 20× magnification. Scale 
bar represents 100 µM. B-D) Quantification of MAP2+ cells treated with indicated 
compounds is shown (repeated measures two-way ANOVA followed by Dunnett’s 
test, n = 3, *p < 0.05, **p < 0.01 vs drug vehicle). Dashed lines represent untreated 
(UT) cultures. 
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Figure 3-2. LPV but not DRV is toxic to primary rat cortical neuroglial cultures 
A) Cultures were treated with DMSO vehicle or 0.1 µM, 1 µM, or 10 µM LPV or DRV 
for 2 days. Representative images of neuroglial cultures immunostained for MAP2 
(green) and DAPI (blue) after treatment with 10 µM of the indicated compounds are 
shown at 20× magnification. Scale bar represents 100 µM. B–C) Quantification of 
MAP2+ cells treated with indicated compounds is shown (repeated measures one-
way ANOVA followed by Dunnett’s test, n = 3, **p < 0.01 vs drug vehicle). Dashed lines 
represent untreated (UT) cultures. D) Neurons were treated with LPV and DRV with 
or without simultaneous RTV or RTV vehicle treatment. RTV booster concentrations 
were given in fixed ratios with LPV and DRV concentrations. Quantification of MAP2+ 
cells treated with indicated compounds is shown (repeated measures two-way 
ANOVA followed by Dunnett’s test, n = 3, *p < 0.05, **p < 0.01 vs drug vehicle). Dashed 
line represents untreated (UT) cultures. 
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Figure 3-3. LPV but not EVG induces oxidative stress  
A) Rat cortical neuroglial cultures were treated with DMSO vehicle or 10 µM LPV or 
EVG for 1h prior to the addition of CellRox Green reagent and live cell imaging.  Images 
captured by time-lapse live imaging were merged with the images of the same cells 
that were subsequently fixed and immunostained for MAP2 and DAPI. Representative 
images captured 30 min following CellRox addition show cells immunostained for 
MAP2 (red), DAPI (blue), and CellRox green at 20× magnification. Scale bar 
represents 100 µM; white arrows indicate examples of neurons that accumulated 
CellRox green dye. B) Quantification of the area positive for CellRox green 
fluorescence normalized to untreated (UT) cultures (dashed line) is shown (repeated 
measures one-way ANOVA followed by Dunnett’s test, n = 4, *p < 0.05 vs drug 
vehicle).  
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Figure 3-4. LPV but not EVG induces the endogenous antioxidant response, 
while EVG but not LPV transiently increases the ratio of peIF2α/teIF2α  
A) Rat cortical neuroglial cultures were treated with DMSO vehicle or 10 µM LPV for 
4, 8, or 20h. Representative blots are shown. FG, fast green loading control. B–D) Band 
intensities of HO-1, BiP, peIF2α, and teIF2α were quantified using ImageJ software. 
HO-1 and BiP are normalized to FG, and peIF2α is normalized to teIF2α (repeated 
measures two-way ANOVA followed by Dunnett’s test, n = 3, *p < 0.05 vs drug 
vehicle). Dashed lines represent untreated (UT) cultures. E) Rat cortical neuroglial 
cultures were treated with DMSO vehicle or 10 µM EVG for 4, 8, or 20 h. 
Representative immunoblots are shown. FG, fast green loading control. F–H) Band 
intensities of HO-1, BiP, peIF2α, and teIF2α were quantified using ImageJ software. 
HO-1 and BiP are normalized to FG, and peIF2α is normalized to teIF2α (repeated 
measures two-way ANOVA followed by Dunnett’s test, n = 3, *p < 0.05, ***p < 0.001 
vs drug vehicle).  Dashed lines represent untreated (UT) cultures.    
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Figure 3-5. Pharmacological induction of HO-1 is protective against LPV-
induced neurotoxicity 
A) Rat cortical neuroglial cultures were pretreated with either DMSO vehicle or 0.1 
µM CDDO for 1 h prior to 20 h treatment with DMSO vehicle or 10 µM LPV. 
Representative immunoblots are shown. GSR, glutathione reductase; FG, fast green 
loading control. B–C) HO-1 and GSR band intensities of were quantified using ImageJ 
software (repeated measures two-way ANOVA followed by Dunnett’s test, n = 3, *p < 
0.05, **p < 0.01 vs drug vehicle, ##p < 0.01 vs CDDO vehicle). D) Cultures were 
pretreated with either DMSO vehicle or 0.1 µM CDDO for 1 h prior to 48 h treatment 
with DMSO vehicle or 10 µM LPV. Representative images of LPV-treated cells 
immunostained for MAP2 (green) and DAPI (blue) are shown at 20× magnification. 
Scale bar represents 100 µM. E) Quantification of MAP2+ cells treated with indicated 
compounds is shown (repeated measures one-way ANOVA followed by Dunnett’s 
test, n = 3, *p < 0.05 vs drug vehicle). F) Cultures were pretreated with DMSO vehicle 
or 0.1 µM CDDO for 1 h prior to 10 µM EVG treatment. After 48 h, cells were re-treated 
with DMSO vehicle or 10 µM EVG for another 48 h, followed by immunostaining. 
Quantification of MAP2+ cells treated with indicated compounds is shown (repeated 
measures one-way ANOVA followed by Dunnett’s test, n = 3, **p < 0.01 vs drug 
vehicle).   
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CHAPTER 4: CONCLUSIONS AND FUTURE 
DIRECTIONS 
 
Overlapping Consequences of HIV and antiretrovirals  
 The studies presented in this dissertation suggest that both HIV 
itself and ARVs may contribute to impairments in neuronal health that 
underlie HAND symptoms. Among many proposed mechanisms by which 
HIV may indirectly affect neurons through macrophage infection, the 
pathway proposed herein implicates a critical role for BACE1 and APP 
cleavage. The mechanism of ARV-induced neurotoxicity investigated in 
this report involves ROS generation by protease inhibitor treatment, but 
this mechanism is not generalizable across ARVs.  
 The work presented here demonstrating a role for BACE1 in HIV-
associated neurotoxicity is an extension of previous work in which the 
protease inhibitor ritonavir directly induced BACE1 in neurons as well 
(Gannon et al. 2017). In this study, BACE1-dependent increased 
amyloidogenic APP processing was also observed in response to ritonavir 
treatment, and pharmacological inhibition of BACE1 was 
neuroprotective. Hence, BACE1 is uniquely involved in mediating toxicity 
of both HIV and protease inhibitors, even in the absence of plaque 
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formation. Future studies are needed to determine if other ARVs also 
induce toxicity through BACE1-dependent pathways, but regardless it is 
promising as a potential therapeutic access point that could address 
multiple causes of neurotoxicity in HAND. The appeal of a BACE1 
inhibition strategy is further highlighted by the success of BACE1 
inhibitors thus far for the treatment of AD. Several brain-penetrant 
compounds with high specificity and low toxicity in animals and humans 
have been developed (Yan and Vassar 2014; Ghosh and Tang 2015); if 
any of these drugs are proven effective in AD treatment following the 
ongoing clinical trials, it will be particularly prudent to consider testing 
BACE1 inhibitors in animal models and potentially HAND patients as 
well.  
 In the second study of this dissertation, we showed that oxidative 
stress is mechanistically linked to neuronal damage caused by lopinavir 
treatment. This result is consistent with our previous report 
demonstrating a role for oxidative stress in both ritonavir- and 
saquinavir-induced neuronal damage (Akay et al. 2014), indicating that 
this may be a shared mechanism across protease inhibitors. Gannon et 
al. 2017 found that ritonavir also induced UPR activation that was 
required for BACE1 increase and neuron loss in vitro; thus, even a single 
drug may lead to neurotoxicity through multiple pathways. Indeed, 
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several reports have identified BACE1 upregulation in neurons due to 
increased ROS production (Tamagno et al. 2012b; Tamagno et al. 2008; 
Tamagno et al. 2002), and indeed one study found that both oxidative 
stress and the UPR were mechanistically involved in a single pathway 
regulating BACE1 levels (Mouton-Liger et al. 2012). Therefore, multiple 
cellular stress pathways initiated either by ARVs or HIV may be activated 
linearly or in parallel to converge on a similar downstream event, such 
as increased BACE1 and consequent neuronal loss.  
 Oxidative stress is likely to be another common mechanism by 
which HIV and ARVs additively or synergistically promote neurotoxicity. 
Infection of monocyte-derived macrophages by HIV increases ROS in 
the extracellular space (Sawada 2009; Olivetta et al. 2005; Olivetta et 
al. 2009), which is toxic to neurons in vitro (Viviani et al. 2001). 
Moreover, the virus initiates a positive feedback loop whereby ROS 
directly increases HIV replication (Nottet et al. 1994). Viral proteins 
gp120 and tat both increase ROS generation in brain endothelial and 
other cell types (Price et al. 2006; Toborek et al. 2003), and multiple 
reports have identified increased oxidative stress in the brains of HIV 
patients post mortem (Mollace et al. 2001). Because our study and 
others indicate that oxidative stress caused directly by ARVs can also be 
implicated in neuronal damage and death (Akay et al. 2014; Tricarico et 
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al. 2016; Shah et al. 2016), brain oxidative stress is likely to be induced 
simultaneously by both HIV and ARVs to result in increased 
neurotoxicity.  
 Under normal physiological conditions, cells can monitor and 
alleviate increases in oxidation by engaging the endogenous antioxidant 
response. This response is triggered by activation of the transcription 
factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and subsequent 
transcription of its downstream antioxidant targets, including heme 
oxygenase 1 (HO-1) and glutathione reductase (GSR) (Lu et al. 2016). 
Elevation of HO-1, GSR, and other Nrf2 targets then reduces oxidant 
levels in the cell to maintain redox balance. Hence, in the present report, 
increasing HO-1 levels with CDDO was sufficient to prevent lopinavir-
induced neurotoxicity associated with ROS increase. As an added 
complication in the oxidative stress component of toxicity, however, the 
ability of neuroglia to mount an endogenous antioxidant response may 
be compromised in the brains of HIV+ patients (Gill et al. 2014). 
Specifically, Gill et al found that viral replication in CNS macrophages 
correlated with decreased HO-1 expression both in vivo and in vitro, and 
in HAND patients, HO-1 deficiency was correlated with degree of 
cognitive impairment. Moreover, pharmacological manipulation of HO-1 
levels in cultured macrophages was sufficient to alter glutamate content 
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and neurotoxicity of the conditioned media. These results in combination 
with the data presented in this report suggest that increased ROS in 
combination with decreased cellular capacity to manage oxidative stress 
may occur simultaneously in HIV+ patient brains to impair neuronal 
function.  
 In addition to disrupting glutamate balance through macrophage 
infection directly, both HIV and ARVs can alter astrocytic function. 
Excitatory amino acid transporter 2 (EAAT-2) expression is decreased in 
astrocytes following treatment with either lopinavir or amprenavir, 
resulting in increased extracellular glutamate (Vivithanaporn et al. 
2016). Additionally, HIV-induced oxidative stress in astrocytes can lead 
to glutamate release through increased glutathione production as well 
as other mechanisms (Vázquez-Santiago et al. 2014; Markowitz et al. 
2007). Lending further support to the proposal that HIV and ARVs act 
in concert to disrupt neuronal function, neurons exposed to ARVs may 
have heightened responses to elevated glutamate concentrations. 
Indeed, Robertson et al, 2012 found that certain prescribed 
combinations of ARVs caused neurons to have exaggerated calcium 
influx in response to glutamate. Altered glutamate response in addition 
to increased extracellular glutamate concentrations could therefore 
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combine synergistically to increase the likelihood of excitotoxic damage 
in HIV+ patient brains.  
 Given the likely contributions of both HIV and ARVs to HAND 
persistence, both high and low CNS penetrance of ARVs may be 
problematic depending on the particular drug and the patient viral load. 
Hence, scientists have the more complex goal of designing ARVs with 
low neurotoxic potential even in high concentrations. To this end, 
several new ARVs are being developed with special consideration for 
their function in the CNS. One avenue being pursued is nanomedicine, 
in which ARVs can be fused with small, lipophilic, brain-specific peptides 
that allow targeted CNS drug delivery. Nano-NRTIs in particular have 
shown recent promise in their ability to suppress brain viral load in 
animal models of HAND without causing the neurotoxic side effects 
associated with standard NRTIs (Gerson et al. 2014). However, 
clinicians should proceed with caution in the use of these drugs given 
that such high ARV concentrations in the CNS are unprecedented and 
low toxicity in animal models may not directly translate to the patient 
population.   
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Expanding upon the role of BACE1 and APP processing 
 Protease inhibitors induce BACE1 in neurons through ER stress 
and the UPR (Gannon et al. 2017), and herein we determined that HIV-
infected macrophage supernatants and NMDAR activation induce 
neuronal BACE1 as well. Hence, BACE1 may provide an attractive 
therapeutic target for neuroprotection in HAND. 
 In order to further elucidate the role of BACE1 and Aβ oligomers 
in HAND, a detailed characterization in a larger cohort of HIV+ patients 
is warranted. Herein, we compared BACE1 expression in prefrontal 
cortex of two independent cohorts, and therefore can confidently 
conclude that BACE1 is increased in HIV+ patients vs. HIV- controls. We 
cannot, however, determine whether BACE1 is a feature of HAND or a 
feature of HIV serostatus regardless of cognitive impairment. BACE1 
may increase susceptibility to neuronal damage and therefore play a 
role in HAND even if levels are not correlated with cognition, but an 
association between increased BACE1 and cognitive dysfunction would 
provide particularly strong rationale for targeting BACE1 in therapeutic 
interventions. Because we have also shown here that Aβ oligomers are 
increased in HIV+ brains and that APP processing is implicated in 
BACE1-mediated neurotoxicity in vitro, it will be critical to determine 
whether Aβ oligomers are increased in HAND patient brains vs. 
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neurocognitively normal controls. Ideally, a large and well-characterized 
cohort of patients across the cognitive spectrum should be used to 
identify differences in both BACE1 and Aβ oligomer expression between 
HIV-, HIV+ neurocognitively normal, ANI, MND, and HAD samples. 
Repetition of results will also be required as even a well-controlled 
cohort will include variability of cART regimen, duration of infection, and 
duration of treatment.  
 Our data strongly implicate a role for excitotoxic mechanisms in 
HAND, as has been suggested elsewhere (Lipton 2004; Cohen et al. 
2015; Lindl et al. 2010). Although we showed that BACE1 upregulation 
is NMDA-dependent, further experiments are needed to address the 
specific NMDAR subunits involved. Typically, NMDARs are tetramers 
composed of at least one NR1 subunit and a combination of NR2A-D 
subunits or NR3A-B subunits, and subunit expression patterns differ 
according to both brain region and developmental stage. NR2A and 
NR2B receptors mediate neurotoxicity of HIV/MDMs (O’Donnell et al. 
2006) and therefore are likely to mediate BACE1 upregulation. This 
prediction can be tested in future experiments by pretreating neurons 
with subunit specific inhibitors such as the NR2B antagonist ifendprodil, 
the NR2A/2B antagonist Conantokin-G, and the NR2A antagonist zinc.  
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 Another important consideration regarding the role of NMDARs in 
our experiments is whether the receptors mediating toxicity are synaptic 
or extrasynaptic. Current evidence suggests that extrasynaptic NMDARS 
mediate excitotoxicity in neurodegenerative disease (Bading 2017), and 
consequently the most advantageous therapies should specifically 
target these receptors while leaving synaptic NMDARs relatively spared. 
Indeed, extrasynaptic NMDARs specifically promote Aβ oligomer 
formation, while synaptic NMDAR activity promotes non-amyloidogenic 
APP processing (Rush and Buisson 2014).  Hence, we expect based on 
our observation of BACE1 increases following NMDA treatment that 
effects were primarily mediated extrasynaptically. This prediction may, 
however, prove difficult to test. The experiments described in this report 
were performed in cortical neurons, which typically express both NR2A 
and NR2B subunits across membrane substructures. Subunit selective 
inhibitors would not therefore provide information about synaptic 
localization. In hippocampal neurons, on the other hand, NR2B receptors 
are primarily extrasynaptic (Bading 2017). Hence, a simple way to 
simultaneously address subunit specificity, synaptic localization, and 
regional generalizability of our results would be to repeat a subset of 
experiments in hippocampal neurons with an additional experiment 
testing the effects of subtype specific NMDAR antagonists on BACE1 
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expression. Relevance of such an experiment is further highlighted by 
our observation of increased Aβ oligomers specifically in hippocampus 
of HIV+ patient brains.    
 Another remaining task is to clarify the mechanism of BACE1 
upregulation in more detail. Although we showed here that increases in 
BACE1 protein expression were dependent on NMDAR activation, the 
mediator linking NMDAR activation with increased BACE1 is not known. 
Ritonavir-mediated BACE1 increases are blocked by inhibition of either 
PERK or protein kinase R (PKR) (Gannon et al. 2017), whereas 
efavirenz-mediated (Brown et al. 2014) and other BACE1 increases are 
dependent on oxidative stress (Mouton-Liger et al. 2012; Tamagno et 
al. 2008; Tamagno et al. 2012a). Cyclin-dependent kinase 5 (cdk5) 
(Sadleir and Vassar 2012), calpain (Liang et al. 2010; Dong et al. 2005), 
and Aβ oligomers themselves (Mamada et al. 2015) have also been 
implicated in mechanisms of BACE1 upregulation. One first step in 
identifying the mediator of BACE1 increases in our model specifically 
would be to determine whether HIV/MDM-induced changes in BACE1 are 
transcription- vs. translation-dependent. For instance, Gannon et al, 
2017 showed that ritonavir-mediated BACE1 upregulation was 
dependent on translation, which was consistent with a mechanism 
involving the UPR. If translational machinery were required for BACE1 
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upregulation by HIV/MDMs or NMDA as well, we could assess the role of 
the UPR by treating neurons harvested from transgenic mice lacking 
PERK or other UPR signaling proteins. On the other hand, if inhibiting 
transcription was sufficient to prevent BACE1 upregulation by HIV/MDM 
or NDMA treatment, it would implicate a potential role for oxidative 
stress (Tamagno et al. 2012b). In this case, the specific mechanism 
could be probed by treating neurons with either free radical scavengers 
such as α-tocopherol (Tamagno et al. 2002) or compounds that activate 
the endogenous antioxidant response such as CDDO or monomethyl 
fumarate (MMF).  
 Another critical aspect of the toxic mechanism that has not been 
addressed here is the link between increased APP processing and neuron 
loss. This topic has plagued the AD research field for decades, and 
unfortunately the reasons for neurotoxicity caused by amyloidogenesis 
are mostly unknown (Yan and Vassar 2014). Both gain-of-function 
toxicity caused by Aβ oligomers (Sengupta et al. 2016) and loss-of-
function toxicity resulting from decreased full-length APP at the synapse 
(Müller et al. 2017) remain plausible causes of neuronal dysfunction. 
However, due primarily to several failed clinical trials targeting Aβ 
species, many have proposed that neuron loss in AD is not related to 
APP processing (Castello et al. 2014) and may instead be driven by 
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another hallmark of AD, neurofibrillary tangles (Giacobini and Gold 
2013). Importantly, although our study suggests that amyloidogenic 
APP processing is related to HIV-associated toxicity in vitro, lessons from 
AD research caution that mechanistic observations may not necessarily 
relate to HAND neuropathogenesis.   
 Animal models of HAND could provide a useful tool in determining 
whether BACE1- and APP-dependent mechanisms are relevant in vivo. 
One of the limitations of our in vitro system is that our primary measure 
of toxicity is frank neuronal loss, which is not observed in HAND in the 
current era (Gelman 2015). This caveat limits the potential 
generalizability of our findings to the more subtle damage observed in 
patients. Because HIV is a human-specific virus, animal models of HAND 
are difficult to develop and often involve multiple genetic manipulations; 
however, they are useful under specific circumstances (Honeycutt et al. 
2015) and can provide powerful insights into the HIV-associated 
mechanisms that impact cognition. Some initial follow-up experiments, 
therefore, could test whether pharmacological BACE1 inhibition is able 
to improve memory or attention in these models. Additionally, further 
in vitro experiments could employ HIV/MDM or NMDA treatments 
titrated to low levels that induce synaptodendritic damage (Everall et al. 
1999) without causing neuron loss. If blocking BACE1 activity prevents 
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damage under these conditions, it would further suggest a potential role 
for BACE1 in HAND.  
 Finally, a separate series of experiments could further explore the 
relevance of the dramatic decrease in ADAM10 we observed following 
NMDA treatment. ADAM10 and its cleavage product sAPPα are 
decreased in AD patients (Colciaghi et al. 2002); surprisingly though, 
other than identification of a role for ADAM10 in HIV-1 replication 
(Endsley et al. 2014), little attention has been paid to its potential 
relevance in HIV. Following our observation, we tested whether ADAM10 
expression was altered in a small cohort of HIV+ vs. HIV- human 
samples of prefrontal cortex. ADAM10 was significantly decreased in 
HIV+ samples, but only in patients who had been taking cART for at 
least six months (data not shown). This result suggests that either A) 
ARVs alone are sufficient to affect ADAM10 expression through 
excitotoxic or other mechanisms, or B) both HIV+ serostatus and ARVs 
are needed in combination to decrease ADAM10. Regardless, a larger 
cohort would first be needed in order to verify that the effect we 
observed is a true feature of cART-treated HIV patients.  
 If human data suggest translational relevance of our ADAM10 
findings, several in vitro experiments could be used to probe potential 
mechanisms linking NMDAR activation to ADAM10 regulation. One such 
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mechanism that has already been identified in vitro is a role for wnt/β-
catenin signaling (Wan et al. 2012); however, this pathway was 
implicated in ADAM10 upregulation following a 90-minute treatment 
with higher NMDA doses, rather than the decrease we observed after 8-
hour exposure. A more promising potential mediator of this decrease 
may be the UPR factor x-box binding protein 1 (XBP-1). NMDA signaling 
can variably affect ER stress and the UPR via changes in calcium influx 
(Prentice et al. 2015), and a canonical signaling protein in the UPR 
cascade is the transmembrane protein inositol-requiring enzyme 1 
(IRE1), which in its activated form can splice XBP-1 mRNA to generate 
an active transcription factor. Spliced XBP-1 mRNA increases ADAM10 
transcription in vitro and is correlated with ADAM10 in post mortem 
human brain tissue. Moreover, AD patient brains have decreased levels 
of both XBP-1 and ADAM10 in comparison with healthy age-matched 
controls (Reinhardt et al. 2014). This is in direct contrast with markers 
of additional UPR pathways such as PERK and activating transcription 
factor 6 (ATF6), which are increased in AD brain (Hoozemans et al. 
2012). 
 Interestingly, a previous report from our lab suggests that XBP-1 
may be implicated in HAND as well. Because it is difficult to assess mRNA 
levels in post mortem tissue, we instead reported changes in levels of 
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the upstream factor IRE1, which was nonsignificantly decreased in HIV+ 
individuals in comparison with HIV- controls (Akay et al. 2012). Lack of 
significance may have been due to the small cohort available, which only 
included four HIV- samples. These data suggest that HIV may cause 
downregulation of the IRE1 pathway, resulting in decreased XBP-1 and 
resultant depletion of ADAM10. Importantly, regulation of ADAM10 at 
the transcriptional level would be consistent with the time course of our 
observation that NMDA treatment does not affect protein levels until at 
least 8-hour exposure.         
 To test this prediction, experiments could first address whether a 
correlation exists between IRE1 or XBP-1 and ADAM10 expression in a 
larger cohort of HIV- and HIV+ patient brain samples. Causation could 
then be tested in vitro using both NMDA treatments and HIV/MDM 
treatments in primary neuronal cultures. If either siRNA knockdown or 
pharmacologic inhibition of IRE1 were able to prevent ADAM10 depletion 
by NMDAR activation, it would suggest that the IRE1 arm of the UPR at 
least has the potential to play a mechanistic role in vivo. However, 
ADAM10 expression is regulated by multiple pathways at the 
transcriptional, translational, and post-translational levels (Endres and 
Deller 2017), and several competing mechanisms may be at play 
downstream of NMDAR signaling.  
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 A related critical pursuit would be to investigate whether loss of 
ADAM10 promotes neurotoxicity in HIV. Evidence suggests this may be 
the case, given that ADAM10 overexpression is protective against both 
plaque formation and memory deficits in AD mouse models (Schmitt et 
al. 2006; Postina et al. 2004). Functional consequences of ADAM10 loss 
could first be investigated by measuring sAPPα concentrations in the 
conditioned media of HIV/MDM- or NMDA-treated neurons. If 
treatments decrease sAPPα concentrations, it could suggest that loss of 
sAPPα contributes to toxicity in our model (Habib et al. 2017; Hefter and 
Draguhn 2017). This could be verified first by testing whether 
pharmacological inhibition of ADAM10 activity confers greater 
susceptibility to NMDA or HIV/MDM treatments in either wild type 
neurons or neurons lacking APP. If results demonstrate a toxicity-
promoting effect of ADAM10 inhibition specifically in wild type but not 
APP-/- neurons, key follow-up experiments should test whether 
overexpression of sAPPα is neuroprotective. Manipulations of sAPPα 
concentration can ultimately then be tested for efficacy in animal models 
of HAND. Importantly, although a role for sAPPα would be scientifically 
interesting, BACE1 is a more attractive therapeutic target due to the 
myriad of relatively selective pharmacologic inhibitors that have already 
been developed and tested for safety (Ghosh and Tang 2015). 
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 This dissertation has addressed two important debates in the field 
of HAND research and treatment: A) whether HAND persistence is 
primarily due to HIV or ARVs, and B) whether pathological features of 
HAND are similar enough to AD that it would be rational to pursue similar 
avenues for treatment of the two diseases. Regarding the first point, our 
data here add to a growing body of evidence that HAND is a 
multifactorial disease driven by both viral infiltration into the CNS as 
well as neurotoxic side effects of therapy. Regarding the second point, 
our data do suggest that BACE1 inhibitors similar to those being tested 
in AD may improve cognition in HAND. Although pathological findings 
are still unclear and HAND brains differ substantially from AD (Ortega 
and Ances 2014), BACE1 is an attractive therapeutic target regardless 
of the disease-specific amyloid pathology. We are hopeful that current 
clinical trials of BACE1 inhibitors in AD will yield positive results, and 
furthermore that these results along with the data presented herein will 
inspire further investigation into the potential benefits of targeting 
BACE1 in HAND.   
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